Autism (“ASD”) is a global problem, with no generally accepted treatment. In the UK alone, between 1998 and 2018, research has found a greater than 780% increase in the number of autism cases
PaxMedica is focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms
The ASD therapeutics market was valued at $2.01 billion in 2023 and is expected to reach $3.42 billion by 2030, growing at a CAGR of 7.9%
There is currently no approved pharmacologic treatment targeting the cause and symptoms. Current treatments only address the condition’s symptoms rather than targeting the pathophysiology itself
Researchers used to believe that autism spectrum disorder only affected one in 2,500 children – today, that estimation is closer to one in 36 children. Between 1998 and 2018, research has found more than a 780% increase in the number of autism cases in the United Kingdom. This significant increase is partially due to the deeper understanding and awareness of autism and the number of physicians who can diagnose the condition (https://ibn.fm/o5oTZ).
Autism spectrum disorder (“ASD”) is a developmental disorder affecting how individuals interact with other people, behavior, communication, and learning. This disorder can be diagnosed at any age, but symptoms often appear in the first two years of life. There is currently no approved pharmacologic treatment targeting the cause and symptoms. Current treatments only address the condition’s symptoms rather than targeting the pathophysiology itself.
PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms, is on a promising path to address the unmet medical needs of ASD, bringing hope to millions. Anti-purinergic therapies target…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, has expanded its executive team as the company positions itself in a growing market. The company has appointed cloud entrepreneur and IT industry veteran Lorenzo Martinelli as its first chief revenue officer and Dr. Trevor Lanting as its chief development officer.
According to the announcement, the new appointments will “supercharge” D-Wave’s go-to-market (“GTM”) growth strategy as well as product innovation. In his new position, Martinelli will oversee sales, marketing, professional services, and customer success as well as spearhead the company’s commercial expansion into key vertical markets. Lanting, who previously served as D-Wave’s senior vice president of software, algorithms and cloud services, will lead D-Wave’s product innovation roadmap, including its full stack of quantum computing hardware and software solutions.
Martinelli has more than three decades of experience in building start-ups from inception to IPO and has served in leadership roles at QAD DynaSys, E2open, AristaSoft, Baan (now Infor), Digital Equipment (now HPE) and IBM. He has an impressive background devising innovative GTM strategies for optimization applications, especially in the company’s key target verticals of logistics and manufacturing, and will be key in executing the company’s growth strategy. Lanting’s new responsibilities include overseeing D-Wave’s product roadmap and initiatives to advance the science of quantum computing as well as helping direct the ongoing development of the company’s Advantage(TM) and Advantage2(TM) annealing quantum computing systems, its gate model computing program, and the interdisciplinary teams focused on performance research and algorithm development.
“This is a watershed moment as enterprise customers are starting to move quantum applications into production,” said D-Wave Quantum CEO Dr. Alan Baratz in the press release. “The expertise and leadership of these two seasoned leaders will be instrumental in executing our GTM strategy, fueling new commercial opportunities and advancing our technology innovation as we continue to demonstrate annealing quantum computing’s impact on customers today.”
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations, including Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California and Los Alamos National Laboratory. For more information about the company, please visit www.dwavequantum.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the implementation of the initiatives established by the NDAA and the development and implementation of other Congressional initiatives related to quantum technology. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the successful implementation of the initiatives and programs established by the NDAA; whether the other pieces of legislation related to Congressional initiatives regarding quantum technology continue to proceed through the legislative process; general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on the company’s business; the risk that D-Wave will need to raise additional capital to execute the company’s business plan, which may not be available on acceptable terms or at all; the risk that D-Wave may never achieve or sustain profitability; the risk that D-Wave is unable to secure or protect the company’s intellectual property; volatility in the price of the company’s securities; the risk that the company’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has announced a 1-for-10 reverse split of the company’s Class A common stock. The move was approved by the company’s board of directors during a special stockholder meeting. According to the announcement, the reverse split will become effective at 11:59 p.m. ET on March 26, 2024. Following that, the company’s Class A common stock will begin trading on the NASDAQ Capital Market on a split-adjusted basis. “The reverse split is intended to increase the per share trading price of the company’s common stock to enable the company to regain compliance with the minimum bid price requirement for continued listing on the NASDAQ Capital Market,” said the company in the press release. “The reverse split will automatically convert every 10 current shares of the company’s common stock, whether issued and outstanding or held by the company as treasury stock, into one share of fully paid and nonassessable common stock.”
Longeveron is a clinical-stage, biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM), an allogeneic mesenchymal stem cell (“MSC”) formulation sourced from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action that promote tissue repair and healing with broad potential applications across a spectrum of disease areas. The underlying mechanism(s) of action that may lead to the tissue repair programs include the stimulation of new blood vessel formation, modulation of the immune system, reduction in tissue fibrosis, and the stimulation of endogenous cells to divide and increase the numbers of certain specialized cells in the body. Longeveron is currently pursuing three pipeline indications: Hypoplastic Left Heart Syndrome, Alzheimer’s disease, and Aging-related Frailty. To learn more about the company, visit www.Longeveron.com.
NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://ibn.fm/LGVN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
The global electric boats market is forecast to more than double in size, increasing from $3.3 billion in 2023 to $7.7 billion by 2030
Vision Marine’s unveiling of its newest e-boat offering, the Phantom, couldn’t have come at more opportune time
The company’s new chief financial officer brings invaluable expertise and insight in manufacturing, production and delivery
As the electric boat sector is projected to double in value in the next few years, companies operating in the industry are positioning themselves to meet — and even exceed — the expectations this growth could create. For example, Vision Marine Technologies (NASDAQ: VMAR), a global leader and innovator in the performance electric recreational boating market, has made two key announcements recently: the company unveiled its Phantom vessel, a new rotomolded, recyclable, and hard-to-damage boat (https://ibn.fm/n0Ytr), and it named an industry veteran as it transitions to the manufacturing and delivery phase (https://ibn.fm/O8OPk).
The global electric boats market is on the cusp of significant growth, with the market forecast to more than double in size, increasing from $3.3 billion in 2023 to $7.7 billion by 2030, reported ResearchandMarket.com (https://ibn.fm/0dMHk). “This remarkable expansion is set to soar at a…
NOTE TO INVESTORS: The latest news and updates relating to VMAR are available in the company’s newsroom at https://ibn.fm/VMAR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”), is focusing its lead program on autism spectrum disorder (“ASD”), for which there is no approved pharmacologic treatment targeting cause and symptoms. “The current ASD treatments only address the symptoms of the condition but do not target the pathophysiology itself. PaxMedica is on a promising path to address the unmet medical needs of families with ASD – bringing hope to millions,” a recent article reads. “PaxMedica is using existing research on a drug called suramin, initially created to treat a disease called Human African Trypanosomiasis (‘HAT’), to support new studies for treating ASD and a related condition known as Fragile X-Associated Tremor/Ataxia Syndrome (‘FXTAS’)… If these trials prove that suramin is effective, PaxMedica could not only get the drug approved for use, but also receive a special coupon from the FDA called a Priority Review Voucher (‘PRV’). This voucher, which can accelerate the review of a new drug, is quite valuable and could be sold to another pharmaceutical company for a significant amount of money. The company intends to channel these funds into conducting extensive trials for ASD and FXTAS treatment through its lead program, PAX-101 (IV Suramin)… In 2024, PaxMedica is positioned to continue its momentum, sustained by achievements in 2023. The company is working to expand its product pipeline, centered on its proprietary source of suramin.”
PaxMedica is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders. Its comprehensive portfolio encompasses a spectrum of conditions, including neurodevelopmental disorders such as autism spectrum disorder (“ASD”), as well as other critical areas within the neurology field. PaxMedica is dedicated to the continuous development and evaluation of its pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of its efforts, particularly focused on innovative ASD treatment solutions. The company’s ongoing research initiatives not only prioritize the needs of ASD patients but also extend to exploring potential therapeutic applications for related conditions. To learn more about PaxMedica and its transformative work, visit www.PaxMedica.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
SOBRsafe (NASDAQ: SOBR) has developed a patent-pending alcohol detection device to detect alcohol in humans with just a single touch of the finger. “SOBRsafe’s alcohol detection technology can improve workplace safety and provide advanced screening and monitoring solutions for the behavioral health industry… SOBRsafe’s next-generation transdermal technology detects and instantaneously reports the presence of alcohol through the user’s skin. No breath, blood or urine samples are required – making it a hygienic alternative to traditional breathalyzers,” a recent article reads. “SOBRsafe’s technology is integrated within the company’s robust and scalable platform, producing statistical and measurable user and business data. The company’s products include: SOBRsafe(TM), SOBRcheck(TM), and SOBRsure(TM).” According to the article, SOBRsafe is the company’s patent-pending platform for non-invasive alcohol detection, with real-time reporting and historical data aggregation. SOBRcheck is the company’s stationary identification and alcohol detection product that provides quick, specific, point-of-care screening. Lastly, SOBRsure is the company’s transdermal, alcohol-detecting wearable band that provides continuous monitoring, discreetly detecting and instantaneously reporting the presence or absence of alcohol by the band wearer.
Alcohol misuse is the fourth leading cause of preventable death in America, and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive and inefficient, unhygienic and unconnected. There has to be a better way. Enter SOBRsafe(TM), where advanced transdermal (touch-based) technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin – no breath, blood or urine sample is required. With a powerful backend data platform, SOBRsafe provides next-generation, passive detection technology for the behavioral health, justice and consumer markets, and for licensing and integration. The SOBRsafe technology is commercially available for access control (“SOBRcheck(TM)”), wearable use (“SOBRsure (TM)”) and licensing/white labeling. SOBRsafe is creating a culture of prevention and support. To learn more, visit www.SOBRsafe.com.
NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
SenesTech, a rapidly growing company specializing in highly effective fertility control solutions for animal pests, recently announced multiple product distribution deals outside the U.S.
In Europe, it entered into an agreement with Q-chem, a pest control product supplier in The Netherlands
In Australia, SenesTech entered into an agreement with Evicom, an environmental management firm with distribution in the country, as well as in New Zealand and the surrounding region
In Asia, the company partnered with Agro Technic PTE Ltd, a pest control product manufacturer and distributor headquartered in Singapore
SenesTech (NASDAQ: SNES), a rodent fertility control solutions provider, and the inventor of the only EPA-registered contraceptive for male and female rats, is pleased to announce multiple distribution deals globally in what marks a huge milestone for the company, just two months into the new year. These deals bring YTD 2024 total revenue up more than 80% compared to YTD 2023 (https://ibn.fm/D9icH).
SenesTech also announced its foray into the European market with its distribution agreement with Q-chem, a pest control product supplier in the Netherlands. The move looks to tap into the growing demand for pest control products and services since the country first implemented an…
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, was featured in a recent episode of First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials. Hosted by Vial EVP Rich McCormick, the podcast is available for on-demand listening on First in Human by Vial. Rob Etherington, president, director and CEO of Clene joined the program to highlight information about the company’s work in the field of nanotechnology. “For decades…the idea of a therapeutic elemental metal having some medicinal efficacy has been well understood. We at Clene had the idea to combine this with the mechanism of a nanotherapeutic, providing, at the atomic level, the ability to drive energy into the failing mitochondria that powers your and my brain,” Etherington said during the interview.
“We first completed some translational medicine work, whereby we were able to show that our drug taken orally got into the stomach then into the bloodstream and then across the blood brain barrier to drive the key bio energetic metabolites that you and I rely upon for energy… we were able to reverse the clock potentially by decades, in terms of key bioenergetic metabolites. We then proceeded into two amyotrophic lateral sclerosis (‘ALS’) studies and one multiple sclerosis study, all of which have concluded in the past 18 months. These studies have shown the ability of CNM-Au8(R) to improve function, which can be translated as how to improve the way patients move and walk and talk and eat and chew and breathe.”
Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company today announced its entry into definitive agreements for the sale and issuance of 1,542,112 shares of its common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 1,542,112 shares of common stock at a combined offering price of $4.215 per share of common stock (or per prefunded warrant in lieu thereof) and accompanying warrant, in a registered direct offering priced at-the-market under the Nasdaq rules. The warrants have an exercise price of $4.09 per share, exercisable on the date of issuance and expiring five years following the date of issuance. Subject to customary conditions, the closing of the offering is expected to occur on or about March 21, 2024. The gross proceeds to Genprex are expected to be approximately $6.5 million, of which the company intends to use the net proceeds for working capital and general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex(R) Delivery System, which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The company’s lead product candidate, Reqorsa(R) Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”). Each of Genprex’s three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and its SCLC program has received an FDA Orphan Drug Designation. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. For more information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GNPX are available in the company’s newsroom at https://ibn.fm/GNPX
CNS Pharmaceuticals recently appointed Amy Mahery, a biotech commercialization leader, to its Board of Directors
Ms. Mahery brings over 20 years’ experience, having worked with small and large companies, and has held diverse commercial leadership roles in the U.S. and globally
The company believes Ms. Mahery’s guidance, insight, and vast pharma industry network will indeed be invaluable as the company advances Berubicin, its flagship drug candidate, toward completion of its global potentially pivotal clinical trial and potential regulatory approval
The company recently completed the enrollment of patients in its potentially pivotal global clinical trial
Ms. Mahery believes Berubicin represents an opportunity to provide a solution for patients with GBM, the most aggressive type of brain cancer
With a fervent commitment to developing and commercializing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system, clinical-stage biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) continues to advance its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization. To boost these efforts, the company has enlisted an experienced, growing team. Recently, CNS Pharmaceuticals appointed Amy Mahery to its Board of Directors (https://ibn.fm/huSZ8).
A biotech commercialization leader, Ms. Mahery has built an illustrious career that spans more than 20 years. During this period, she has gained commercial expertise working with small and large companies in common and rare conditions, as well as across several therapeutic areas. She has held diverse…
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Lexaria, a global innovator in drug delivery platforms, recently received FDA clearance for its HYPER-H23-1 clinical study
John Docherty, President of Lexaria, has regarded this milestone as a demonstration of its patented DehydraTECH(TM) technology’s overall viability, particularly in the potential treatment of hypertension
With HYPER-H23-1, Lexaria looks to build on the success of its previous human clinical studies, whose results have been overwhelmingly positive
This marks a considerable milestone even as the company looks to double down on GLP-1 studies for the 2024 calendar year
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced that the U.S. Food and Drug Administration (“FDA”) has given it the requisite clearance to proceed with its planned U.S. Phase 1b hypertension clinical trial. This follows the company’s Investigational New Drug (“IND”) application earlier in the year.
The HYPER-H23-1 clinical trial, entitled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” will seek to explore the overall effectiveness of its patented…
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CBDWire
CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.
CBDW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CBDWire, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer
D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, plans to release its financial results for the fourth quarter and fiscal year 2023 for the period ended Dec. 31, 2023 before market open on March 28, 2024.
In addition, the company has scheduled a conference call that same day to discuss the financial report along with the company outlook; the call is scheduled to begin at 8 a.m. ET. D-Wave CEO Dr. Alan Baratz and CFO John Markovich will host the call. Those wanting to access the call can dial 1-800-267-6316 (domestic) or 1-203-518-9783 (international).
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations, including Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California and Los Alamos National Laboratory. For more information about the company, please visit www.dwavequantum.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the implementation of the initiatives established by the NDAA and the development and implementation of other Congressional initiatives related to quantum technology. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the successful implementation of the initiatives and programs established by the NDAA; whether the other pieces of legislation related to Congressional initiatives regarding quantum technology continue to proceed through the legislative process; general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on the company’s business; the risk that D-Wave will need to raise additional capital to execute the company’s business plan, which may not be available on acceptable terms or at all; the risk that D-Wave may never achieve or sustain profitability; the risk that D-Wave is unable to secure or protect the company’s intellectual property; volatility in the price of the company’s securities; the risk that the company’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Turbo Energy (NASDAQ: TURB) is a designer, developer and manufacturer of photovoltaic energy generation, management and storage equipment. The company is seeking to harness artificial intelligence (“AI”) in the manufacture and development of its residential solutions, which allow households to capture and store solar energy. “The company’s ‘Sunbox Home’ system encompasses an all-in-one AI-powered energy storage solution, designed to assist households in managing their power consumption. Directly linked to a household’s solar panel generation unit, the Sunbox system allows users to choose between settings including ‘maximum consumption’ or ‘maximum savings,’ to conserve a portion of its energy reserves in the event of unexpected electricity blackouts or rather, sell excess power back onto the grid. The groundbreaking energy storage system additionally boasts the capacity to track weather forecasts, thus ensuring its batteries are fully charged in the event of a storm,” explains a recent article. “Turbo Energy’s artificial intelligence and optimization system is the best on the market,” said Turbo Energy CEO Mariano Soria. “[In addition to having] the capacity to offer the end consumer the best solution in economic savings, [our] software is the basis for the continued development of the company [as well as giving us] the ability to incorporate other elements in the future. We envision the ability to make use of it, not only for individuals but for groups such as energy communities or virtual power plants.”
Turbo Energy is a leading photovoltaic energy storage technology company based in Valencia, Spain. The company develops innovative solutions that allow end users to harness the full potential of solar energy and reduce their electricity costs. With a combination of artificial intelligence and advanced technology, Turbo Energy is paving the way toward a more sustainable and energy-efficient future. For more information, visit the company’s website at www.Turbo-E.com.
NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB
About GreenEnergyStocks
GreenEnergyStocks (“GES”) is a specialized communications platform with a focus on companies working to shape the future of the green economy. GreenEnergyStocks is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GES is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, GES brings its clients unparalleled recognition and brand awareness. GES is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from GreenEnergyStocks, text “Green” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the GreenEnergyStocks website applicable to all content provided by GES, wherever published or re-published: https://www.greennrgstocks.com/Disclaimer
SenesTech (NASDAQ: SNES) is dramatically improving pest management technicians’ toolboxes with its patent-pending Evolve(R) soft bait birth control product for rodents, which joins the liquid ContraPest(TM) product in providing non-lethal solutions to reducing rodent populations. “The patent-pending Evolve(TM) soft bait has a sausage-like appearance and poses little or no risk to human health or the environment – a significant advantage over poisons used to kill rats. SenesTech’s products are the first, and still the only, such rat contraceptives registered with the U.S. Environmental Protection Agency (‘EPA’) that target both male and female rats… The company recommends using its Birth Control for Rats(TM) products in tandem with other rodent control products, since rats that consume Evolve(TM) or ContraPest(R) will continue to live out their life cycles for months, just without adding new generations of pups. But SenesTech’s products can be used on their own if preferred,” a recent article reads. “The company’s reach is expanding globally – in addition to outlets across the United States, government entities in South Africa, the Maldives and, last month, the United Arab Emirates (‘UAE’) market have entered agreements with the company.”
SenesTech is committed to improving the health of the world by humanely managing animal pest populations through fertility control. The company is an expert in fertility control to manage animal pest populations. It invented ContraPest(R), the only U.S. EPA-registered contraceptive for male and female rats, and Evolve(TM), an EPA-designated minimum risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. SenesTech strives for clean cities, efficient businesses and happy households – with a product designed to be humane, effective and sustainable. For more information about the company, visit www.SenesTech.com.
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced the publication of peer-reviewed research, titled “Protein Corona Composition of Gold Nanocrystals.” The publication appeared in the journal ACS Pharmacology & Translational Science and fully characterized the proteins from human blood plasma that form the protein corona of the gold nanocrystals of CNM-Au8(R), Clene’s investigational drug in development for the treatment of neurodegenerative diseases. “The protein corona of CNM-Au8 gold nanocrystals, tailored for brain delivery applications, exhibits a unique composition, notably enriched with critical apolipoproteins such as apolipoprotein E. This composition enhances the nanocrystals’ ability to traverse the blood-brain barrier. Simultaneously, the depletion of opsonin-based proteins in the corona extends their circulation time in the blood, as observed clinically. Our research underlines that these engineered gold nanocrystals, designed with specific structures and without surfactants, can form a distinct protein corona that facilitates access to brain tissue,” said Morteza Mahmoudi, associate professor in the Precision Health program and Department of Radiology at the Michigan State University College of Human Medicine.
Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
EU raised 2030 binding renewable energy target to a minimum of 42.5%, aims to become climate-neutral by 2050
U.S. set goal of 100% clean energy by 2035
TURB aligned with renewable energy shift with Sunbox Home and Sunbox Industry
TURB’s all-in-one systems leverage AI to improve efficiency, prevent price shocks, and maximize cost savings
Turbo Community allows members with large PV installations to gain ownership of production, store extra power, and sell energy to market
The European Union recently raised its 2030 binding renewable target to a minimum of 42.5% with the aim of reaching 45% and becoming a climate-neutral continent by 2050 (https://ibn.fm/djHTQ). Across the Atlantic, the United States has set an even more ambitious goal of 100% clean energy by 2035 (https://ibn.fm/cqFtw).
Turbo Energy (NASDAQ: TURB), a photovoltaic energy company based in Spain, is strongly positioned to capitalize on the growing trend with its comprehensive range of patented energy storage and management solutions. By aligning its products and services with the evolving…
NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB
About GreenEnergyStocks
GreenEnergyStocks (“GES”) is a specialized communications platform with a focus on companies working to shape the future of the green economy. GreenEnergyStocks is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GES is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, GES brings its clients unparalleled recognition and brand awareness. GES is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from GreenEnergyStocks, text “Green” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the GreenEnergyStocks website applicable to all content provided by GES, wherever published or re-published: https://www.greennrgstocks.com/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has appointed a new chief financial officer. The company announced that, effective immediately, Nelson Cabatuan, CPA, will serve in the position, which also entails being a member of Lexaria’s executive leadership team. Cabatuan brings more than 15 years of corporate finance and operations experience in the life sciences industry. Most recently, he served as senior vice president of finance and operations at Rain Oncology Inc., a late-stage precision oncology biotech company. In that position, he was pivotal in building and leading the company’s financial organization, resulting in significant growth while he was there. Cabatuan also held several positions at Rigel Pharmaceuticals Inc., including vice president finance. “Nelson’s deep financial leadership experience will be instrumental to the execution of Lexaria’s long-term growth strategy as we continue to maximize the potential use of our DehydraTECH platform for GLP-1 and other therapeutic applications with high unmet medical needs,” said Lexaria Bioscience CEO Chris Bunka in the press release. “On behalf of the entire Lexaria team, I’m thrilled to welcome Nelson as our CFO.”
Lexaria Bioscience’s patented drug-delivery formulation and processing platform technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has begun enrolling the first patients in its VALID-ECG pivotal study. According to the announcement, the first patients were enrolled at Atlanta Heart Specialists, a top cardiology physician practice in Atlanta, Georgia. HeartBeam anticipates the VALID-ECG study will form the basis of its planned FDA 510(k) submission. The study is designed to evaluate the performance of a 12-lead ECG synthesized from the credit-card-sized HeartBeam AIMIGo(TM) system compared to a standard hospital-based 12-lead ECG; the study will use both quantitative and qualitative methodologies for assessment of arrhythmias. The company anticipates enrolling some 198 patients in the program. “The initiation of the VALID-ECG study is a major milestone for the company and a reflection of our commitment to provide a strong foundation of clinical data as we strive to provide patients and physicians with the ability to accurately monitor cardiac disease outside of a medical facility,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “In addition, our product pipeline includes coupling AI with our data-rich 3D VECG technology, which will enable us to extract unique information and longitudinal insights to transform how cardiac care is monitored in the future.”
HeartBeam is a medical technology company dedicated to transforming cardiac care through the power of personalized insights. The company’s proprietary vectorelectrocardiography (“VECG”) technology collects 3D signals of the heart’s electrical activity and converts those signals into a 12-lead ECG. This platform technology is designed to be used on portable, patient-friendly devices such as a credit-card-sized monitor, watch or patch. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care, all outside of a medical facility, thus redefining how cardiac health is managed. For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Freight Technologies recently announced a significant collaboration with Envases Universales, one of the world’s largest packaging companies
The collaboration, anchored in a contract estimated to be valued at over $5 million, is intended to help manage Envases’ transportation needs over the next year
According to Fr8Tech, the contract demonstrates Fr8App’s commitment to delivering exceptional transportation services as well as its ability to meet the evolving needs of its clients
The collaboration with Envases Universales follows a Jan. 2024 contract with Kawasaki Motores de Mexico for cross-border logistics services
Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company, recently announced that its custom-developed, industry-leading Fr8App freight matching platform has been selected by Envases Universales, one of the world’s largest packaging companies, to help manage Envases’ transportation needs over the next 12 months. According to the company, Fr8App was awarded 24 dedicated routes, mostly from Mexico to the U.S., through Envases’ annual 2024 request for quotation (“RFQ”) (https://ibn.fm/0E0rw).
Powered by artificial intelligence (“AI”), machine learning, and cloud computing, the F8App freight-matching platform offers a real-time portal for B2B cross-border and domestic shipping within the USMCA region. It seamlessly connects shippers with an extensive network of carriers and…
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, announced that CEO Dr. Alan Baratz and CFO John Markovich will present at the 36th Annual Roth Conference. The three-day event is scheduled for March 17–19, 2024, in Dana Point, California. According to the announcement, Dr. Baratz will also participate in a fireside chat scheduled for 1 p.m. PT on March 19. A replay of the fireside chat will be available following the presentation.
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations, including Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California and Los Alamos National Laboratory. For more information about the company, please visit www.dwavequantum.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the implementation of the initiatives established by the NDAA and the development and implementation of other Congressional initiatives related to quantum technology. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the successful implementation of the initiatives and programs established by the NDAA; whether the other pieces of legislation related to Congressional initiatives regarding quantum technology continue to proceed through the legislative process; general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on the company’s business; the risk that D-Wave will need to raise additional capital to execute the company’s business plan, which may not be available on acceptable terms or at all; the risk that D-Wave may never achieve or sustain profitability; the risk that D-Wave is unable to secure or protect the company’s intellectual property; volatility in the price of the company’s securities; the risk that the company’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today provided an update on the U.S. Customs and Border Protection (“CBP”) application for Class 1 EV cargo vans. According to the announcement, the CBP, on March 5, 2024, informed Rapid Response Defense Systems (“RRDS”) counsel that a final determination on the ruling request needs to be issued by the U.S. General Services Administration (“GSA”). Based on CBP advice, Mullen and RRDS are proceeding with the GSA in order to finalize qualification of Mullen to sell Class 1 EV cargo vans to all branches of the U.S. government. “Mullen is well positioned to support the U.S. government’s goal of transitioning its fleet to electric vehicles,” said David Michery, CEO and chairman of Mullen Automotive.
Mullen is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. For more information about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. The comprehensive overview showcases PaxMedica’s strategic direction, recent advancements in autism spectrum disorder (“ASD”) therapeutics, and its commitment to addressing unmet needs within the ASD community. “PaxMedica is pleased to share our vision and progress with the wider community,” said Howard Weisman, chairman and CEO of PaxMedica. “We believe that our work has the potential to transform the treatment landscape for ASD, offering a new horizon of hope and support for affected individuals and their loved ones.”
PaxMedica is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders. Its comprehensive portfolio encompasses a spectrum of conditions, including neurodevelopmental disorders such as autism spectrum disorder (“ASD”), as well as other critical areas within the neurology field. PaxMedica is dedicated to the continuous development and evaluation of its pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of its efforts, particularly focused on innovative ASD treatment solutions. The company’s ongoing research initiatives not only prioritize the needs of ASD patients but also extend to exploring potential therapeutic applications for related conditions. To learn more about PaxMedica and its transformative work, visit www.PaxMedica.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced its full year 2023 financial results. In addition, the company provided recent operating highlights for the clinical programs in amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “In 2024 we will continue to advance our regulatory discussions with the U.S. Food and Drug Administration (‘FDA’) that we anticipate will include new data on biomarkers, as well as additional clinical function and survival data in people living with ALS,” said Rob Etherington, president and CEO of Clene. “Having held our initial discussion with the FDA in the fourth quarter of last year, we have a clear understanding of the additional data required to support an accelerated approval pathway filing for CNM-Au8(R). We believe that we can provide additional supportive evidence to advance discussions with the FDA with the potential to file an NDA later this year.”
Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has received a Notice of Patent Grant from the Korean Patent Office. The patent, which is effective through 2037, covers the use of the company’s lead drug candidate, Reqorsa(R) Immunogene Therapy, in combination with anti-PD-1 and PD-L1 antibodies. According to the announcement, this newest patent expands on previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors applicable to the company’s Acclaim-2 and Acclaim-3 clinical trials. Previous patents have been granted by authorized entities in the United States, Japan, Mexico, Russia, Australia, Chile and China. “We continue to secure exclusivity for our drug combinations of REQORSA with PD-1 antibodies, such as Keytruda(R), and PD-L1 antibodies, such as Tecentriq(R), for the treatment of cancer in some of the largest markets,” said Genprex senior vice president of intellectual property and licensing Thomas Gallagher in the press release. “It is important that we continue to add to our global intellectual property estate and to build protection around our drug combinations as we advance REQORSA through the clinic.”
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes that currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, nonviral Oncoprex(R)Nanoparticle Delivery System, which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that are deficient in the tumor. The company’s lead product candidate, REQORSA(R) Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”). Each of Genprex’s three lung cancer clinical programs has received a fast-track designation from the Food and Drug Administration for the treatment of that patient population, and Genprex’s SCLC program has received an FDA Orphan Drug Designation. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus (“AAV”) vector to deliver Pdx1 (“Pdx1”) and MafA (“MafA”) genes directly to the pancreas. In models of type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. For more information, please visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GNPX are available in the company’s newsroom at https://ibn.fm/GNPX
Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high performance lidar solutions, today announced that it will provide a business update and release its financial results for the fourth quarter and full year 2023 following the close of the market on Thursday, March 28, 2024. On that same day at 2:30 p.m. PT (5:30 p.m. ET), Cepton will hold a conference call and webcast. Interested parties should dial 1-877-423-9813 (toll-free) or 1-201-689-8573 (international) to join the live call and visit https://investors.cepton.com to access the webcast. A telephonic replay will be available approximately three hours after the call as detailed in the announcement.
Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D perception solutions across industries. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to automotive customers in the Metro Detroit area. Cepton also has a presence in Germany to serve European customers. For more information, visit the company’s website at www.Cepton.com.
NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing CDMO services through its Scinai Bioservices business unit, will be participating at this month’s BIO-Europe Spring 2024 conference. The conference is scheduled for March 18–20, 2024, in Barcelona. According to the announcement, Scinai management will be attending the event and will be available for discussions with prospective clients, potential pharma partners that may be interested in co-advancing or in-licensing Scinai’s innovative NanoAb for the treatment of mild to moderate plaque psoriasis, and institutional and private investors. In addition, the company is hosting a booth in the conference exhibition space showcasing the company’s cGMP biologics CDMO and innovative NanoAb pipeline.
Scinai Immunotherapeutics is a biopharmaceutical company with two complementary business units: one focused on in-house development of inflammation and immunology (“I&I”) biological products beginning with an innovative, derisked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO (“CDMO”) providing biological drug development, analytical methods development, clinical GMP manufacturing, and preclinical and clinical trial design and execution services to early-stage biotech companies. For more information, visit the company’s website at www.Scinai.com.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
SOBRsafe (NASDAQ: SOBR), providers of next-generation transdermal alcohol detection solutions, has unveiled a new behavioral-health webinar series. The slate of webinars will include industry leaders and focus on cutting-edge best practices. The first segment in the series is titled “The Future of Alcohol Monitoring Is Here: Discover Touch-Based Detection with SOBRsafe.” Hosted by Jason Wahler, a recovery advocate and TV personality, the webinar will include invaluable insight from several subject matter experts, including Keenen Diamond, president and COO of Oceanfront Recovery; Wendy Stine, a certified interventionist and addictions counselor; and Matt Mitchell, transdermal technology veteran and director of partnerships for SOBRsafe. The webinar is scheduled for March 27, 2024, at 3 p.m. ET.
SOBRsafe offers an advanced transdermal (touch-based) technology that detects and instantaneously reports in real time the presence of alcohol as emitted through a user’s skin — no breath, blood or urine sample is required. Alcohol misuse is the fourth leading cause of preventable death in America and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive, inefficient, unhygienic and unconnected. There has to be a better way. Enter SOBRsafe. With a powerful backend data platform, SOBRsafe provides next-generation, passive-detection technology for the behavioral health, judicial and consumer markets, as well as for licensing and integration. The SOBRsafe technology is commercially available for point-of-care screening (SOBRcheck) and continuous monitoring (SOBRsure). SOBRsafe is creating a culture of prevention and support. For more information about SOBRsafe, visit www.SOBRsafe.com.
NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at http://ibn.fm/SOBR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Studies have proven that Electronic Monitoring (“EM”) solutions reduce reoffending within 24 months by 16%, and for individuals aged 30 years and under, it reduces reoffending by 43%
These solutions have also been shown to reduce criminal justice costs by about $30,000 for each eligible offender
With such benefits and the validation that comes with governments around the world adopting EM solutions, SuperCom anticipates a significant uptick in the demand for EM solutions
SuperCom (NASDAQ: SPCB), a global leading provider of traditional and digital identity solutions offering advanced safety, identification, and security products, projects an uptick in demand for Electronic Monitoring (“EM”) solutions. This stems from the growing realization and acknowledgment of the effectiveness of these solutions when correctly applied, having proven to reduce reoffending and criminal justice costs.
A study published by the IZA Institute of Labor Economics noted that EM solutions, such as SuperCom’s One-Piece GPS Tracking and Two-Piece GPS Tracking, reduced reoffending within 24 months by 16% compared to serving a prison sentence. It was further noted that for offenders aged 30 years or less, the…
NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, was one of three companies listed in a recent InvestorPlace article titled “ChatGPT Stock Predictions: 3 Quantum Computing Companies the AI Bot Thinks Have 10X Potential.” International Business Machines (NYSE: IBM) and Nvidia (NASDAQ: NVDA) were the other two companies mentioned.
The article noted that the field of quantum computing may just be the next big thing, as it has the potential to solve complex problems that generally slow down classical computers. Examples of utilizing the technology include addressing challenges that involve processing vast quantities of data, making complex forecasts, and leveraging artificial intelligence capabilities.
After highlighting that D-Wave has introduced annealing quantum computing, a quantum computing technique that allows greater potential for commercial applications and that differs from the gate-based techniques that IBM and Google employ, the author concluded his summary on D-Wave stating, “The market seems excited about D-Wave Quantum’s prospects. The firm’s share price has nearly doubled on a year-to-date basis making a 10 times long-term return more of a reality.”
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations, including Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California and Los Alamos National Laboratory. For more information about the company, please visit www.DWaveQuantum.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the implementation of the initiatives established by the NDAA and the development and implementation of other Congressional initiatives related to quantum technology. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the successful implementation of the initiatives and programs established by the NDAA; whether the other pieces of legislation related to Congressional initiatives regarding quantum technology continue to proceed through the legislative process; general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on the company’s business; the risk that D-Wave will need to raise additional capital to execute the company’s business plan, which may not be available on acceptable terms or at all; the risk that D-Wave may never achieve or sustain profitability; the risk that D-Wave is unable to secure or protect the company’s intellectual property; volatility in the price of the company’s securities; the risk that the company’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Fr8Tech recently participated in the Geotab Connect 2024 event as a marketplace partner, covering insights into connected vehicles, data intelligence, artificial intelligence, and sustainability
Last year, the company integrated its Fr8App freight-matching platform with Geotab’s open API, boosting real-time visibility and efficiency for shippers and carriers
Fr8Tech recently secured a cross-border logistics services contract with Kawasaki Motores de Mexico, a division of manufacturing conglomerate Kawasaki Heavy Industries, Ltd.
Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company developing solutions to optimize and automate the supply chain process and freight logistics, recently participated in the prestigious Geotab Connect 2024 event as a distinguished marketplace partner. The Geotab Connect 2024 took place in Las Vegas February 14 to 16, 2024, delivering unparalleled insights into the ever-evolving landscape of connected vehicles, data intelligence, artificial intelligence, and sustainability (https://ibn.fm/jbgKE).
“We are thrilled to continue being marketplace partners with such a prominent company in the technology and logistics industry like Geotab. Fr8App has been able to significantly enhance the user experience for shippers and carriers on its platform with Geotab’s telematics, and we look forward to…
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Astrotech (NASDAQ: ASTC), a science and technology company focused on commercializing its innovative platform mass spectrometry technology through its wholly owned subsidiaries, recently released financial results for Q2 2024. “The company recorded a 512% jump in its year-to-date (‘YTD’) revenue to $1,540,000 from $301,000 in the comparative period a year before. Astrotech attributed this growth primarily to two significant purchase orders for the TRACER 1000(TM) explosive trace detectors (‘ETDs’) to customers in Romania, which the company, through 1st Detect Corp., successfully delivered on. The subsidiary 1st Detect develops, manufactures and sells mass-spectrometer-based trace detectors – including the TRACER 1000(TM), the world’s first mass spectrometer-based ETD – for use in the security and detection markets,” a recent article reads. “A recent SNS Insider article confirms that ‘the Explosive Trace Detection Market is witnessing significant growth driven by increasing security concerns, particularly in transportation, critical infrastructure and public spaces.’ Specifically, it indicates: ‘The Explosive Trace Detection Market, valued at USD 1137.50 million in 2022, is projected to achieve a significant milestone, reaching USD 2250.60 million by 2030.’ This market is yet another fast-growing and important opportunity for 1st Detect and the superior mass spectrometry technology it offers.”
Astrotech is an innovative science and technology company that invents, acquires and commercializes technological innovations while building scalable companies to maximize shareholder value. For more information, please visit www.AstrotechCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Lexaria, a global innovator in drug delivery platforms, has, since 2016, proven its patented DehydraTECH(TM) technology, asserting its superiority in improving drug bioavailability
This has earned it 39 granted patents, with many pending globally
DehydraTECH has a number of potential pharmaceutical applications with successful early stage results in hypertension, diabetes and weight loss and many others With its focus on GLP-1 clinical studies for 2024, Lexaria looks to carve out greater market share to make 2024 its biggest year
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has been pushing the envelope and redefining drug delivery technology. Its patented DehydraTECH(TM) technology has proven itself in numerous studies since 2016, highlighting its ability to increase bio-absorption compared to standard industry formulations while also reducing time of onset, as well as delivering drugs more effectively across the blood brain barrier (https://cnw.fm/iZZZR).
The technology’s effectiveness and uniqueness have earned it 39 granted patents, with many patents pending globally. DehydraTECH has a number of potential pharmaceutical applications, a testament to its versatility and overall effectiveness. The key factor that has played a role in its adoption is its…
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
One in 36 children are diagnosed with autism spectrum disorder (“ASD”) – with ASD four times more common among boys than girls
The SenseToKnow app accurately predicted eventual autism diagnoses in a group of 475 children – according to the study, performance was similar across sex, race, and ethnicity
PaxMedica is leveraging historical data on the drug suramin to fund trials aimed at treating Autism Spectrum Disorder and Fragile X-Associated Tremor/Ataxia Syndrome
According to the CDC, about 1 in 36 children are diagnosed with autism spectrum disorder (“ASD”) – with ASD four times more common among boys than girls (https://ibn.fm/06kly). Currently, there is no medical test to diagnose ASD, and families often face a delay in receiving a diagnosis. Doctors must rely on developmental history and the behavior of the child to make an ASD diagnosis. A diagnosis in girls and children with minority backgrounds often has a longer wait time due to the challenges in finding appropriate experts and the variable symptoms that accompany the disorder.
In a study published in Nature Magazine, researchers introduced a digital screening device that uses machine learning to analyze different behavioral aspects to assess the likelihood of childhood ASD. The SenseToKnow app accurately predicted eventual autism diagnoses in a group of…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to perform the company’s second DehydraTECH-powered glucagon-like peptide 1 (“GLP-1”) human pilot study #2. According to the announcement, the study will be a randomized, crossover, placebo-controlled investigation that will compare three formulations, each at a 7 mg semaglutide dose: a positive control Rybelsus(R) swallowed tablet; DehydraTECH-semaglutide swallowed capsules; and, for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. “DehydraTECH has previously shown an ability to improve delivery of certain drugs destined for the bloodstream, through the buccal/sublingual tissues of the mouth and throat,” said Chris Bunka, CEO of Lexaria. “If this new study is successful in demonstrating efficacy and safety, the potential for a new era in GLP-1 delivery without the need for painful injections or stomach-upsetting tablets could be within reach.”
DehydraTECH(TM) is Lexaria’s patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has received notification that two of its patents covering core vectorelectrocardiography (“VECG”) have been awarded by the United States Patent and Trademark Office. The two new patents bring the total of issued patents in HeartBeam’s portfolio to 14, with four international patents as well; the company also has 20 pending patent applications worldwide. HeartBeam’s VECG technology collects 3D signals of the heart and converts them into a 12-lead ECG. The first awarded patent, “Mobile three-lead cardiac monitoring device and method for automated diagnostics,” covers apparatuses and methods that facilitate the comparison of cardiac signals over time for the automated or assisted detection of heart attacks, or acute myocardial infarction (“AMI”).
The second patent, “Apparatus for generating an electrocardiogram” covers methods and apparatuses around HeartBeam’s wrist-based ECG system, is related to HeartBeam’s watch concept, which features a continuous ECG monitor with the ability to take a high sensitivity 12-lead ECG, combined in a single device that can be worn on the wrist. “HeartBeam’s core VECG technology is designed to be used with portable, patient-friendly devices such as a credit-card sized system, an extended wear patch, or watch to enable physicians to monitor patients and identify cardiac health trends outside of a medical facility,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “These new patents reinforce our strategic vision which is founded on developing and protecting our novel VECG technology and product pipeline as we work to transform how cardiac care is delivered in the future.”
HeartBeam is a medical technology company dedicated to transforming cardiac care through the power of personalized insights. The company’s proprietary vectorelectrocardiography (“VECG”) technology collects 3D signals of the heart’s electrical activity and converts those signals into a 12-lead ECG. This platform technology is designed to be used on portable, patient-friendly devices such as a credit-card-sized monitor, watch or patch. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care, all outside of a medical facility, thus redefining how cardiac health is managed. For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
SOBRsafe (NASDAQ: SOBR), providers of next-generation transdermal alcohol detection solutions, has announced a new customer: Breyta House, a sober-living facility located in Houston. The facility empowers women on their journey to recovery and overall wellness. Bretya House will initially be installing SOBRcheck(TM) for point-of-care alcohol screening. Sober-living facilities, or recovery housing, is a recovery support service specifically for those working to recover from substance-use issues. According to the announcement, there are currently an estimated 17,934 recovery homes located in the United States.
“With our ability to provide both point-of-care screening and continuous monitoring, we believe that we are uniquely positioned to support all components of behavioral health,” said SOBRSafe chair and CEO Dave Gandini in the press release. “Already we have been adopted for inpatient, residential and outpatient uses, as well as for facility and practice-management software integration. We deeply align with the mission of Breyta House, and we are proud to add our advanced technology to its cutting-edge sober living model.”
SOBRsafe offers an advanced transdermal (touch-based) technology that detects and instantaneously reports in real time the presence of alcohol as emitted through a user’s skin — no breath, blood or urine sample is required. Alcohol misuse is the fourth leading cause of preventable death in America and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive, inefficient, unhygienic and unconnected. There has to be a better way. Enter SOBRsafe. With a powerful backend data platform, SOBRsafe provides next-generation, passive-detection technology for the behavioral health, judicial and consumer markets, as well as for licensing and integration. The SOBRsafe technology is commercially available for point-of-care screening (SOBRcheck) and continuous monitoring (SOBRsure). SOBRsafe is creating a culture of prevention and support. For more information about SOBRsafe, visit www.SOBRsafe.com.
NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at http://ibn.fm/SOBR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., will be represented at this month’s annual Roth Conference. The conference will be held March 18–19, 2024, in Dana Point, California. According to the announcement, company officials are scheduled to present a fireside chat, slated to begin at 8 a.m. PST on March 18, 2024. Clene focuses on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). An archived version of the presentation will be available following the webcast on the company website.
Clene and its wholly owned subsidiary, Clene Nanomedicine, is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
Turbo Energy (NASDAQ: TURB), a photovoltaic energy storage innovator, recently forged a collaboration with Solar360, a joint venture of Repsol and Telefónica España, signaling a promising beginning for the company in 2024. “In this partnership, Turbo Energy will supply technology while Solar360 will take on the responsibility of promoting services by installing Turbo Energy’s smart batteries in residential, commercial and industrial locations across Spain. The two companies join forces in a bid to optimize user savings and ensure energy availability beyond sunny periods. Aligning with their shared objective, this collaboration appears well-matched in the rapidly expanding solar photovoltaic self-consumption sector. Turbo Energy aspires to revolutionize solar energy consumption through innovative AI-driven solutions, enabling consumers to optimize solar potential and cut electricity costs for a more sustainable and energy-efficient future. Solar360 combines Telefónica’s technological and IoT expertise with Repsol’s experience in self-consumption to offer tailored electricity rates and comprehensive solar panel installations for individual customers, communities and businesses,” a recent article reads. “Sunbox, Turbo Energy’s flagship product, is the first to be launched by Solar360. As an all-in-one energy solution integrating an inverter, battery and AI-powered software, Sunbox seeks to manage and store photovoltaic energy efficiently through a user-friendly mobile application.”
Turbo Energy is a leading photovoltaic energy storage technology company based in Valencia, Spain. The company develops innovative solutions that allow end users to harness the full potential of solar energy and reduce their electricity costs. With a combination of artificial intelligence and advanced technology, Turbo Energy is paving the way toward a more sustainable and energy-efficient future. For more information, visit the company’s website at www.Turbo-E.com.
NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB
About GreenEnergyStocks
GreenEnergyStocks (“GES”) is a specialized communications platform with a focus on companies working to shape the future of the green economy. GreenEnergyStocks is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GES is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, GES brings its clients unparalleled recognition and brand awareness. GES is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from GreenEnergyStocks, text “Green” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the GreenEnergyStocks website applicable to all content provided by GES, wherever published or re-published: https://www.greennrgstocks.com/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be presenting its research at next month’s 2024 American Association for Cancer Research Annual Meeting. The gathering is slated for April 5–10, 2024, and will be held in San Diego, California. According to the announcement, GNPX’s research collaborates will present positive preclinical data from studies of its lead product candidate, Reqorsa(R)Immunogene Therapy (quaratusugene ozeplasmid) and NPRL2 gene therapy; both treatments use Genprex’s non-viral Oncoprex(R)Delivery System for the treatment of lung cancer. Three Genprex-supported posters are scheduled for presentation during the event. The first, titled “Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing Non-Small Cell Lung Carcinoma can induce cellular apoptosis,” is scheduled for presentation on April 7 from 1:30–5 p.m. PT. The second, titled “Tumor Suppressor Gene TUSC2 suppresses energy metabolism in lung cancer cells with opposite effects in normal bronchial epithelial cells,” is slated for April 8 from 1:30–5 p.m. PT. And the third, titled “Mechanism of NPRL2 gene therapy induced anti-tumor immunity in KRAS/STK11 MTaPD1 resistant metastatic NSCLC,” will be presented on April 8 from 9 a.m.–12:30 p.m. PT.
“We are delighted to have our academic partners present this compelling body of preclinical evidence that support the therapeutic use of REQORSA to deliver the functioning TUSC2 gene to cancer cells,” said Genprex chair, president and CEO Rodney Varner in the press release. “The data also highlights the potential use of our non-viral ONCOPREX Delivery System to deliver other tumor suppressor genes, such as the NPRL2 gene. We are pleased to have favorable results from three preclinical studies presented to an audience of global oncology specialists, providing further validation of the value of REQORSA and ONCOPREX in the fight against cancer.”
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes that currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, nonviral Oncoprex(R)Nanoparticle Delivery System, which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that are deficient in the tumor. The company’s lead product candidate, Reqorsa(R) Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”). Each of Genprex’s three lung cancer clinical programs has received a fast-track designation from the Food and Drug Administration for the treatment of that patient population, and Genprex’s SCLC program has received an FDA Orphan Drug Designation. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus (“AAV”) vector to deliver Pdx1 (“Pdx1”) and MafA (“MafA”) genes directly to the pancreas. In models of type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. For more information, please visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GNPX are available in the company’s newsroom at https://ibn.fm/GNPX
D-Wave and NEC Australia announced two new quantum offerings for Australia’s commercial sector, federal and state governments, and academia
The companies’ new quantum services aim to optimize business operations and can navigate increasingly large datasets to find solutions to real-world problems
New offerings include a quantum consultancy service and access to D-Wave’s Leap(TM) real-time quantum cloud service
D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and NEC Australia recently announced the introduction of two new quantum services to the Australian market, enhancing the quantum computing offerings available to Australia’s commercial sector, federal and state governments, and academia (https://ibn.fm/x9b2Y).
The quantum technology services from NEC Australia and D-Wave can optimize business operations faster than classical computers and navigate increasingly large datasets to find solutions to real-world problems, including logistics and…
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the implementation of the initiatives established by the NDAA and the development and implementation of other Congressional initiatives related to quantum technology. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the successful implementation of the initiatives and programs established by the NDAA; whether the other pieces of legislation related to Congressional initiatives regarding quantum technology continue to proceed through the legislative process; general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on the company’s business; the risk that D-Wave will need to raise additional capital to execute the company’s business plan, which may not be available on acceptable terms or at all; the risk that D-Wave may never achieve or sustain profitability; the risk that D-Wave is unable to secure or protect the company’s intellectual property; volatility in the price of the company’s securities; the risk that the company’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
SenesTech (NASDAQ: SNES), the rodent-fertility control experts and inventors of ContraPest(R), the only EPA-registered contraceptive for male and female rats, will be presenting at the Emerging Growth Conference, which is scheduled for March 6, 2024. According to the announcement, key company leaders will deliver a webcast presentation; the presentation will include time for a Q&A. The presentation is slated to begin at 1:10 p.m. ET. An archived replay of the presentation will be available on the Emerging Growth YouTube channel following the webcast. In addition, SenesTech representatives will be available for one-on-one investor meetings.
SenesTech is committed to improving the health of the world by humanely managing animal-pest populations through fertility control. SenesTech is an expert in fertility control to manage animal pest populations. The company invented ContraPest, the only U.S. EPA-registered contraceptive for male and female rats, and Evolve, an EPA-designated minimum-risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest-management programs, significantly improving the overall goal of effective pest management. The company strives for clean cities, efficient businesses and happy households by providing a product designed to be humane, effective and sustainable. For more information about the company, please visit www.SenesTech.com.
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details for an eight-week animal study, WEIGHT-A24-1, to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 (“GLP-1”) drugs and DehydraTECH-processed cannabidiol, alone and in combination. The contract for the study was awarded to a third-party, Health Canada-licensed research laboratory. Manufacturing of the compositions for the first eight of the 12 study arms has been completed, and those arms will commence as soon as possible at the testing laboratory, expected to begin within 45 days. Each arm of the study will be dosed for eight weeks following an acclimation period. During the study, over 1,500 blood plasma samples will be collected from the total rat population of 72 animals for the purpose of analyzing detailed pharmacokinetic drug delivery. Body weight and blood glucose readings will be taken prior to the start of the study and at regular intervals during and at conclusion of the dosing period. Upon completion of the study, brain tissue will be analyzed to help determine whether DehydraTECH processing results in higher brain absorption than non-DehydraTECH arms, as Lexaria has evidenced numerous times in previous animal studies.
DehydraTECH(TM) is Lexaria’s patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced that it will hold a conference call to discuss its results for the fourth quarter and full fiscal year ended Dec. 31, 2023. During the call, slated to begin at 4:30 p.m. ET on Wednesday, March 20, 2024, HeartBeam executives will also provide regulatory updates, reviewing ongoing initiatives and anticipated 2024 milestones. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno, Consulting CFO Richard Brounstein, and VP of Regulatory Affairs Deborah Castillo, PhD, will host the call, followed by a question-and-answer period. Interested parties should dial 1-877-704-4453 or 1-201-389-0920 (international) and enter conference code 13743963 to join the call and visit https://ibn.fm/E7ZWO to register for and access the webcast. A telephone replay will be available as detailed in the announcement.
HeartBeam is a medical technology company that is dedicated to transforming cardiac care through the power of personalized insights. The company’s proprietary vectorelectrocardiography (“VECG”) technology collects 3D signals of the heart’s electrical activity and converts them into a 12-lead ECG. This platform technology is designed to be used on portable, patient-friendly devices such as a credit-card sized monitor, watch or patch. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining how cardiac health is managed in the future. For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
SOBRSafe (NASDAQ: SOBR), providers of next-generation transdermal alcohol detection solutions, is collaborating with an existing behavioral health customer to expand the use of its proprietary SOBRsafe(TM) technology. SOBRSafe announced that the customer, which is not named for patient privacy reasons, has adopted the SOBRsure wearable band for continuous monitoring in an outpatient scenario; the customer had previously installed SOBRcheck in one of its facilities for point-of-care screening. “This customer is consistent with our approach to the behavioral health market — sign providers with multiple uses for our technology, prove its efficacy and expand within the account,” said SOBRsafe chair and CEO Dave Gandini in the press release. “We are pleased to announce this dual adoption of both SOBRcheck and SOBRsure, and to again demonstrate our technology’s strong utility across the full continuum of care.”
SOBRsafe offers an advanced transdermal (touch-based) technology that detects and reports in real time the presence of alcohol as emitted through a user’s skin — no breath, blood or urine sample is required. Alcohol misuse is the fourth leading cause of preventable death in America and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive, inefficient, unhygienic and unconnected. There has to be a better way. Enter SOBRsafe. With a powerful backend data platform, SOBRsafe provides next-generation, passive-detection technology for the behavioral health, judicial and consumer markets, as well as for licensing and integration. The SOBRsafe technology is commercially available for point-of-care screening (SOBRcheck) and continuous monitoring (SOBRsure). SOBRsafe is creating a culture of prevention and support. For more information about SOBRsafe, visit www.SOBRsafe.com.
NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at http://ibn.fm/SOBR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, announced that its subsidiary, Bollinger Motors, is expanding its footprint. The company has named an additional two dealership groups as it rolls out its commercial truck line. The two dealership groups — Nacarato Truck Centers and Nuss Truck and Equipment — span seven states and include 11 locations. A U.S.-based company headquartered in Michigan, Bollinger Motors develops all-electric commercial chassis cab trucks. The company is beginning its rollout with its B4 Chassis Cab, an all-new, all-electric Class 4 commercial truck designed from the ground up with extensive fleet and upfitter input, which is scheduled for release during the second half of 2024. “We are building our national dealer network very strategically to ensure that they share Bollinger’s commitment to quality and customer service,” said Bollinger Motors founder and CEO Robert Bollinger in the press release. “These two dealership groups represent some of the busiest trucking hubs in the country, and we welcome these new locations to the Bollinger family as we work to electrify fleets across the country.”
Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. In 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive and Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
This success has been attributed largely to the company’s development and recent release of its Evolve soft bait product, a key addition to its growing product line
Year to date 2024, SenesTech reported 80% year-to-date revenue growth compared to the same period in 2023
Going forward, the company looks to introduce a soft bait contraceptive product for mice, having proven that its products work effectively on rats
SenesTech (NASDAQ: SNES), a rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats, just released its financial results for the 2023 financial year. Of note was the 80% year-to-date (“YTD”) revenue growth and the 45.2% year-over-year (“YOY”) growth in gross profit, a significant milestone which Joel Fruendt, President and CEO of SenesTech attributed to the development of Evolve(TM), the company’s all-new soft bait product (https://nnw.fm/mYQOl). (https://ibn.fm/ykfl9).
“Since the full launch of Evolve in January 2024, we have seen a significant uptick in interest and orders from a wide range of sales channels and…
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting glucose reduction and weight-loss results in a testing of its wholly owned and patented DehydraTECH-CBD formulation. According to the announcement, when administered to rodents in an eight-week study, DehydraTech-CBD resulted in weight loss of 7% and a reduction of 19.9% (p<0.05) in blood glucose. As a result, Lexaria has now signed contracts to begin a large, multiweek animal study that will substantially progress its DehydraTECH-GLP-1 and DehydraTECH-CBD weight-loss investigations. In addition, the announcement also noted that the company had published results of a human study, which showed that a single 7 mg semaglutide dose from Rybelsus(R) processed with DehydraTECH, was absorbed at a significantly higher level than without DehydraTECH processing; results of that testing showed that the treatment also managed blood glucose levels more effectively without any blood glucose spiking after eating.
“Together, these discoveries strongly support additional investigations, including determining whether daily dosing of DehydraTECH-GLP-1 might result in sustained higher concentrations of GLP-1 in blood over an extended treatment duration than without DehydraTECH processing and whether such a higher blood concentration might result in greater weight loss over time; and determining whether DehydraTECH-CBD, specially formulated for diabetes control and weight loss, alone and/or in conjunction with DehydraTECH-GLP-1, might also result in greater weight loss and/or blood glucose control over time,” said the company in the press release. “Manufacturing of the test articles for 8 of the 12 arms of the new animal study has already been completed, and dosing in those arms will commence as soon as the third-party laboratory is able to do so, expected to begin within 45 days.”
Lexaria Bioscience’s patented drug-delivery formulation and processing platform technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
Astrotech (NASDAQ: ASTC) is a mass spectrometry company that, through its wholly owned subsidiary 1st Detect, has developed and rolled out the breakthrough TRACER 1000(TM) Explosive Trace Detector (“ETD”). “The world’s first mass spectrometry-based ETD certified by the European Civil Aviation Conference (‘ECAC’), the TRACER 1000(TM) is designed to outperform the ETDs currently used at aviation checkpoints as well as borders, cargo facilities and other secured points around the world. It is powered by the Astrotech Mass Spectrometer (‘AMS’) Technology that is inexpensive, smaller and easier to use when compared to traditional mass spectrometers. The AMS Technology works under ultra-high vacuum, which eliminates competing molecules, resulting in higher resolution and fewer false alarms,” a recent article reads. “Astrotech nonetheless believes that ETD customers are unsatisfied with the currently deployed ETD technology, which is driven by ion mobility spectrometry (‘IMS’)… Against this backdrop and as many of the tens of thousands of IMS instruments deployed in the field near their end of life and need replacement, Astrotech is working to position its TRACER 1000(TM) product as the next-generation solution for the ETD market. ‘Based on our near-zero false alarm rate, we believe that the TRACER 1000(TM) improves checkpoint efficiency and passenger throughput by reducing the need for time-consuming and invasive secondary screenings that cost airports millions in lost merchandise and food sales,’ said Thomas B. Pickens III, chairman and CEO of 1st Detect.”
Astrotech is an innovative science and technology company that invents, acquires and commercializes technological innovations while building scalable companies to maximize shareholder value. For more information, please visit www.AstrotechCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
SenesTech (NASDAQ: SNES), an animal pest control innovator, created its own unique niche within the pest control market after introducing its non-lethal liquid ContraPest(R) bait. “Instead of poisoning rats, the bait targets fertility reduction in male and female rats, and Evolve(TM) has a similar mechanism of action but in a soft bait presentation preferred over liquids by pest management professionals (‘PMPs’) and residential customers. SenesTech’s products are the first, and still the only, such rat contraceptives for both males and females registered with the U.S. Environmental Protection Agency (‘EPA’) designed to be non-lethal,” a recent article explains. “The company conducted studies of ContraPest’s effectiveness at poultry farms on the east and west coasts of the United States, through the farms’ integrated pest management programs. The studies showed that SenesTech’s product cut the rat population in half in three months and produced a sustained 90% reduction over the 12-month study at the western facility, and that pullet survival from predation rebounded by 88% at the eastern facility – delivering hundreds of thousands of dollars in benefits in the process.”
SenesTech is committed to improving the health of the world by humanely managing animal pest populations through fertility control. The company is an expert in fertility control to manage animal pest populations. It invented ContraPest(R), the only U.S. EPA-registered contraceptive for male and female rats, and Evolve(TM), an EPA-designated minimum risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. SenesTech strives for clean cities, efficient businesses and happy households – with a product designed to be humane, effective and sustainable. For more information about the company, visit www.SenesTech.com.
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
Vision Marine Technologies Inc. (NASDAQ: VMAR), a trailblazer in electric recreational boating, today announced Raffi Sossoyan as its new chief financial officer (“CFO”). Sossoyan brings a wealth of experience, with over 25 years in global financial and operational leadership. In his recent role as VP, corporate treasury at Velan Inc. (TSX: VLN), a Canadian multinational company, he managed financial operations amidst global sales exceeding US$370 million. According to the announcement, Sossoyan’s tenure as CFO at Valtech Fabrication Inc., where he drove worldwide sales beyond US$50 million, further highlights his capacity to spearhead financial growth and success. “This strategic appointment marks a significant step as Vision Marine gears up for an ambitious phase focused on manufacturing, production and delivery, underlining the company’s dedication to scaling its operations and enhancing its market footprint,” the announcement noted. “With the appointment of Raffi Sossoyan as CFO, Vision Marine Technologies is poised to navigate its next phase of growth with enhanced financial acumen and strategic direction.”
Vision Marine Technologies epitomizes the marine industry’s shift toward electric propulsion, offering the pioneering E-Motion(TM) outboard powertrain system. This innovative technology represents a significant leap forward in marine propulsion, combining advanced battery packs, inverters and high-efficiency motors with proprietary software and assembly techniques. Vision Marine’s commitment to eco-friendly electric powerboats is reshaping the recreational boating experience, offering higher speeds, longer ranges and smoother rides than traditional internal combustion engine boats. With a focus on design, innovation and craftsmanship, Vision Marine continues to redefine recreational boating for a more sustainable future.
NOTE TO INVESTORS: The latest news and updates relating to VMAR are available in the company’s newsroom at https://ibn.fm/VMAR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that the U.S. Food and Drug Administration (“FDA”) has confirmed the effectiveness of the company’s investigational new drug (“IND”) application thereby clearing Lexaria to conduct its planned U.S. Phase 1b hypertension clinical trial HYPER-H23-1 utilizing DehydraTECH-CBD. According to the announcement, the company is pleased to have complied with the FDA’s rules and procedures for clearance to perform this important registrational trial. The company will further announce when it is ready to begin the study, subject to certain conditions, including raising sufficient funding. “This is a significant milestone achievement for Lexaria demonstrating, for the first time, that its DehydraTECH technology meets the FDA’s high level of regulatory scrutiny sufficient to formally commence U.S. registrational clinical testing towards possible future pharmaceutical commercialization,” said John Docherty, president of Lexaria. “We look forward to commencing this important clinical trial and building upon the wealth of early stage clinical data we have gathered and presented to the FDA to date demonstrating the safety, efficacy and novel mechanistic performance of DehydraTECH-CBD in hypertensive patients.”
DehydraTECH(TM) is Lexaria’s patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
Artificial Intelligence (“AI”) has become an increasingly prominent tool in the battle against climate change
AI can now be used across a myriad of use cases, ranging from tracking small-scale deforestation through to measuring the melting rate of the polar icecaps
Turbo Energy has looked to harness AI technologies within its core product portfolio, including its SunBox and GoSolar home energy systems
AI has emerged as a key tool within solar energy management systems, driving efficiency and lowering costs across the solar energy production supply chain
Home to over 5 million square kilometers of tropical rainforest and storing over 200 petagrams (1 petagram = 1 billion tons) of carbon, the Amazon Basin ranks amongst the world’s most important ecosystems with direct implications for both, regional and global climate. Nevertheless, and until recently, authorities were unable to track the rise of small-scale deforestation taking place across significant swathes of the Amazon rainforest. Forest loss within the Amazonia has been monitored by the Brazilian Institute for Space Research (“INPE”) since 1988; however, INPE studies are woefully limited in scope. The research agency’s focus has historically been confined to the Brazilian Amazon, with its technology solely able to track disturbances greater than 6.25 hectares in area (equivalent to approximately 8 football fields) (https://ibn.fm/1QinW). Now, and capitalizing on the technological advances offered by artificial intelligence, companies such as Scotland-based Space Intelligence are able to remotely map millions of hectares of land from space using satellite data, with the company’s innovative technology able to track metrics such as ongoing deforestation rates or calculate the carbon storage content within a forest (https://ibn.fm/nqdSZ).
Whether it is tracking ongoing deforestation rates around the world, predicting weather patterns to help communities better adapt to climate change, or measuring the meltwater released by icebergs on a real-time basis, the use of AI is gaining ever increasing prominence in the battle against…
NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
SuperCom, a global leading provider of traditional and digital identity solutions, is pushing its EM solutions, specifically in the field of preventing domestic violence
Its products and services have so far been adopted by various governments and institutions around the world, among them two recent new clients in North America
According to Ordan Trabelsi, SuperCom’s President and CEO, this is a testament to the undeniable effectiveness and reliability of the company’s solutions
SuperCom (NASDAQ: SPCB), a global leading provider of traditional and digital identity solutions offering advanced identification and security products and solutions to governments, has, since 1988, been a trailblazer and leader in its space. So far, it has carved out a significant market share globally, and this all stems from a deep understanding of the problems on the ground and offering sustainable and practical solutions that have proven, time and time again, to work.
Its offender monitoring services and solutions are evidence of this. By combining its SuperCom Electronic Monitoring (“EM”) platform with LCA’s EM programs and community-based services, SuperCom can deliver efficient operations, outstanding compliance, and highly successful…
NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. The company is on a promising path to address unmet medical needs of ASD patients. “The prevalence of ASD in the United States has risen to approximately 1 in 36 children, according to the Centers for Disease Control and Prevention (‘CDC’). There are currently no approved pharmacologic treatments that target the causes and symptoms of ASD – the treatment available on the market addresses symptoms of the condition rather than targeting the pathophysiology itself,” a recent article explains. “PaxMedica intends to continue into 2024 with the momentum it has gained with its achievements during the past year. The company is building a robust product pipeline to allow people with ASD to successfully integrate their behavior with others and improve their lives. Its lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting APT known for over 100 years.”
PaxMedica is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders, including autism spectrum disorder (“ASD”) and human African trypanosomiasis (“HAT”). Its portfolio encompasses critical areas within the neurology field, with a focus on pioneering advancements in both ASD and HAT treatments. The company is dedicated to the continuous development and evaluation of its pioneering program, PAX-101-an intravenous suramin formulation that lies at the heart of its efforts, particularly focused on innovative ASD and HAT treatment solutions. PaxMedica’s ongoing research initiatives not only prioritize the needs of ASD and HAT patients but also extend to exploring potential therapeutic applications for related conditions. For more information about the company, visit www.PaxMedica.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
Vision Marine Technologies (NASDAQ: VMAR), a global leader and innovator in the performance electric recreational boating industry, was spotlighted in a recent InvestorPlace article titled “Three Electric Boat Stocks That Will Sail Higher by 2024.” “The article calls Vision Marine a key player in the electric boat stocks market, noting that despite some challenges, the company’s recent ‘strategic moves suggest a promising future…’ The article noted VMAR’s partnership with 4ocean, along with its expansion into the pontoon market, which shows ‘strategic diversification’ a move that InvestorPlace says ‘could be a game changer for Vision Marine, showcasing its adaptability and innovation in the market,” reads a recent article, which contains excerpts from the InvestorPlace piece. “[InvestorPlace] observes that ‘the company’s acquisition of industrial tooling to enhance its production capabilities is a strategic step. It aims to support the production of over 10,000 battery packs annually, meeting the increasing demand for electric marine propulsion systems. Despite financial headwinds, Vision Marine Technologies is positioning itself as a forward-thinking leader in the electric boat industry.’”
Vision Marine Technologies strives to be a guiding force for change and an ongoing driving factor in fighting the problems associated with waterway pollution by disrupting the traditional boating industry with electric power, in turn directly contributing to zero pollution, zero emission and a noiseless environment. Its flagship E-Motion(TM) 180E electric marine powertrain is the first fully electric purpose-built outboard powertrain system that combines an advanced battery pack, inverter and high efficiency motor with proprietary union assembly between the transmission and the electric motor design utilizing extensive control software. The company’s E-Motion(TM) and related technologies used in this powertrain system are uniquely designed to improve the efficiency of the outboard powertrain and, as a result, enhance both range and performance. Vision Marine continues to design, innovate, manufacture and sell handcrafted, environmentally friendly, electric recreational boats to customers. The design and technology applied to its boats results in far greater enhanced performance in general, higher speeds and longer range. Simply stated, a smoother ride than a traditional internal combustion engine (“ICE”) motorboat.
NOTE TO INVESTORS: The latest news and updates relating to VMAR are available in the company’s newsroom at https://ibn.fm/VMAR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Turbo Energy (NASDAQ: TURB), a designer, developer and manufacturer of photovoltaic energy generation, management and storage equipment, has sought to take advantage of the dramatic increase in renewable energy demand, which has been driven by the decline in renewable energy costs and the exponential rise in fossil fuel prices. “Turbo Energy has looked to capitalize on the growing transition toward renewable energy and sustainable residential energy supplies through its revolutionary ‘SunBox Home’ energy storage solution. The company’s ‘SunBox Home’ system encompasses an all-in-one AI-powered energy storage solution, designed to assist households in managing their power consumption. Directly linked to a household’s solar panel generation unit, the SunBox system allows users to choose between settings including ‘maximum consumption’ or ‘maximum savings,’ conserve a portion of its energy reserves in the event of unexpected electricity blackouts or rather, sell excess power back into the grid. The groundbreaking energy storage system additionally boasts the capacity to track weather forecasts, thus ensuring its batteries are fully charged in the event of a storm,” a recent article explains.
Turbo Energy is a leading photovoltaic energy storage technology company based in Valencia, Spain. The company develops innovative solutions that allow end users to harness the full potential of solar energy and reduce their electricity costs. With a combination of artificial intelligence and advanced technology, Turbo Energy is paving the way toward a more sustainable and energy-efficient future. For more information, visit the company’s website at www.Turbo-E.com.
NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB
About GreenEnergyStocks
GreenEnergyStocks (“GES”) is a specialized communications platform with a focus on companies working to shape the future of the green economy. GreenEnergyStocks is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GES is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, GES brings its clients unparalleled recognition and brand awareness. GES is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from GreenEnergyStocks, text “Green” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the GreenEnergyStocks website applicable to all content provided by GES, wherever published or re-published: https://www.greennrgstocks.com/Disclaimer
SOBRsafe (NASDAQ: SOBR) (“SOBRsafe(TM)”), a provider of next-generation transdermal alcohol detection solutions, today announced that the Oglala Lakota Nation is adopting the SOBRcheck(TM) technology for use in its community-wide probation management program. The Oglala Lakota Nation is a self-governing nation within the U.S., and its Pine River Reservation in South Dakota is the eighth-largest Native American reservation in the country. “Our law enforcement function is resource-constrained, so we are always seeking ways to innovate and gain operational efficiencies,” said Warren Cross, lab director, Oglala Sioux Tribe Clinical Lab. “SOBRcheck is faster and cleaner than the legacy breathalyzer method, both freeing up staff time and creating a safer work environment. Moreover, it brings dignity to detection in a tightly knit community. We don’t seek to embarrass our friends and neighbors – SOBRcheck helps remove that emotion from the alcohol screening process.”
Alcohol misuse is the fourth leading cause of preventable death in America, and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive and inefficient, unhygienic and unconnected. There has to be a better way. Enter SOBRsafe(TM), where advanced transdermal (touch-based) technology detects and reports in real time the presence of alcohol as emitted through a user’s skin – no breath, blood or urine sample is required. With a powerful backend data platform, SOBRsafe provides next-generation, passive detection technology for the behavioral health, judicial and consumer markets, and for licensing and integration. The SOBRsafe technology is commercially available for access control (“SOBRcheck(TM)”), wearable use (“SOBRsure (TM)”) and licensing/white labeling. SOBRsafe is creating a culture of prevention and support. To learn more, visit www.SOBRsafe.com.
NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that the U.S. Food and Drug Administration (“FDA”) has confirmed the effectiveness of the company’s investigational new drug (“IND”) application thereby clearing Lexaria to conduct its planned U.S. Phase 1b hypertension clinical trial HYPER-H23-1 utilizing DehydraTECH-CBD. According to the announcement, the company is pleased to have complied with the FDA’s rules and procedures for clearance to perform this important registrational trial. The company will further announce when it is ready to begin the study, subject to certain conditions, including raising sufficient funding. “This is a significant milestone achievement for Lexaria demonstrating, for the first time, that its DehydraTECH technology meets the FDA’s high level of regulatory scrutiny sufficient to formally commence U.S. registrational clinical testing towards possible future pharmaceutical commercialization,” said John Docherty, president of Lexaria. “We look forward to commencing this important clinical trial and building upon the wealth of early stage clinical data we have gathered and presented to the FDA to date demonstrating the safety, efficacy and novel mechanistic performance of DehydraTECH-CBD in hypertensive patients.”
DehydraTECH(TM) is Lexaria’s patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has moved to the next phase in testing an integrated solid-state polymer battery pack in its Class 1 EV cargo vans. According to the announcement, vehicle road testing began this week on the battery pack. The company began initial lab testing of the latest phase of solid-state polymer battery packs in January by installing the battery pack in the Class 1 EV cargo van to monitor system compatibility between the vehicle and pack; performance testing also included on-road drive cycles and Dyno testing at an EPA-certified lab. The company initially estimated that the battery pack would result in a 73% increase range of the EV, from 110 miles to 190 miles; however, testing has shown an actual 86% increase in vehicle range from 110 miles to 205 miles. “The first road test has resulted in significant gains in vehicle range,” said Mullen Automotive CEO and chair David Michery in the press release. “Additional testing over time will solidify a solid-state solution for our commercial vehicles. Next steps include finalizing our design and manufacturing validation.”
Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. In 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive and Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has released a financial report for the year ended Dec. 31, 2023; the report also included a corporate update. The report noted that revenues for 2023 totaled $0.7 million with grant revenue for 2023 being less than $0.1 million; related cost of revenues was $0.5 million for 2023; and gross profit for the year came in at approximately $0.2 million. In addition, general and administrative expenses totaled $11.4 million for 2023; research and development expenses decreased to approximately $9.1 million with selling and marketing expenses for 2023 reaching $0.8 million. In addition, as of Dec. 31, 2023, the company had $5.4 million in cash and cash equivalents and marketable securities. “In 2023 we made significant strides advancing studies of our investigational product, Lomecel-B, in hypoplastic left heart syndrome (‘HLHS’) and Alzheimer’s disease, with long-term survival data from ELPIS I trial presented at the American Heart Association annual meeting and clinically meaningful results announced from our phase 2a CLEAR MIND clinical trial of Lomecel-B(TM) in the treatment of mild Alzheimer’s disease,” said Longeveron CEO Wa’el Hashad in the press release. “For 2024, our main strategic priority will be focused on our lead clinical program in HLHS, our most important near-term value driver.
Accordingly, we made the strategic decision to discontinue our phase 2 clinical program in Aging-Related Frailty in Japan. We are also exploring opportunities to advance our Alzheimer’s disease program through potential partnerships or other sources of funding. These steps will allow us to focus our available resources on completing enrollment in our follow-on ELPIS II study in 2024. HLHS patients are in critical need of new therapeutic options to improve outcomes in this rare and life-threatening indication.”
Longeveron is a clinical-stage, biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action encompassing provascular, proregenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently advancing Lomecel-B through clinical trials in three indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty. To learn more about the company, visit www.Longeveron.com.
NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://ibn.fm/LGVN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., is reporting on the full clinical results for CNM-Au8(R), an investigational first-in-class therapy designed to improve central nervous system cells’ survival and function. Clene, which is focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), presented the results at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum in Florida. The results were gathered from the VISIONARY-MS trial long-term open label extension (“LTE”) in participants with stable relapsing multiple sclerosis (“RMS”) totaling nearly three years of follow-up. According to the announcement, data gathered from the clinical trial indicate that long-term CNM-Au8 treatment results in “significant and clinically meaningful” improvement of vision and improvement of cognition. In addition, the company noted that treatment was well-tolerated, with no serious adverse events attributed to CNM-Au8 and no significant safety findings reported. The report noted that after completion of the double-blind period, 55 of 69 LTE-eligible study participants continued on CNM-Au8 30mg for up to an additional 96 weeks.
Clene and its wholly owned subsidiary, Clene Nanomedicine, is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, has unveiled a six-module quantum training course designed for beginner quantum programmers. Called “Foundations for Quantum Programming,” the self-paced, online course teaches essential mathematics and Python skills and prepares individuals to continue on to successfully take D-Wave’s flagship course, “Quantum Programming Core.”
The course includes video presentations, quizzes and hands-on programming activities that will assist students in learning to identify optimization problem objectives and variables, represent problem objectives as mathematical expressions, convert constraints to penalty functions and write basic Python programs for quantum programming. The course takes about 10 hours to complete.
“Quantum computing isn’t just for specialists,” said D-Wave global head of technical advising Victoria Goliber in the press release. “We’re equipping employees across roles to take advantage of this technology now. From students to experienced professionals, our expanding learning programs are key to building a quantum-ready workforce to accelerate the adoption of quantum technologies.”
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations, including Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California and Los Alamos National Laboratory. For more information about the company, please visit www.dwavequantum.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the implementation of the initiatives established by the NDAA and the development and implementation of other Congressional initiatives related to quantum technology. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the successful implementation of the initiatives and programs established by the NDAA; whether the other pieces of legislation related to Congressional initiatives regarding quantum technology continue to proceed through the legislative process; general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on the company’s business; the risk that D-Wave will need to raise additional capital to execute the company’s business plan, which may not be available on acceptable terms or at all; the risk that D-Wave may never achieve or sustain profitability; the risk that D-Wave is unable to secure or protect the company’s intellectual property; volatility in the price of the company’s securities; the risk that the company’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
SuperCom Ltd. (NASDAQ: SPCB), a provider of secured solutions for e-Government, IoT and cybersecurity sectors, aims to revolutionize public safety worldwide through proprietary electronic monitoring technology, data intelligence and complementary services. “SuperCom’s proprietary PureSecurity suite is an all-in-one, field-proven offender monitoring system, with services such as GPS monitoring, home detention, domestic violence prevention, and more. The suite is specifically tailored to meet each client’s needs. By leveraging the power of AI, SuperCom’s PureSecurity platform can offer new capabilities, such as amplified data analysis, predictive modeling and streamlined automation – geared toward optimizing decision making and operational efficiency… SuperCom’s PureSecurity suite for electronic monitoring under court-ordered programs includes the company’s GPS digital tracking platform PureTrack, the PureTag wearable RF bracelet, the PureOne one-piece tracking device, and the home-based PureCom station,” a recent article reads. “Ordan Trabelsi, SuperCom’s president and CEO, said that the company was uniquely positioned to capitalize on the increasing global demand for secured electronic monitoring solutions and is strategically investing in continuous improvement of its offerings, extending its reach into new markets, which is already yielding promising results in the U.S. and other regions.”
Since 1988, SuperCom has been a global provider of traditional and digital identity solutions, providing advanced safety, identification and security solutions to governments and organizations, both private and public, throughout the world. Through its proprietary e-Government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance and border control services, SuperCom has inspired governments and national agencies to design and issue secure multi-ID documents and robust digital identity solutions to its citizens and visitors. SuperCom offers a unique all-in-one field-proven RFID & mobile technology and product suite, accompanied by advanced complementary services for various industries including healthcare and homecare, security and safety, community public safety, law enforcement, electronic monitoring, livestock monitoring, and building and access automation. For more information about the company, visit www.SuperCom.com.
NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company whose custom-developed, industry leading Fr8App freight-matching platform offers a real-time portal for B2B cross-border and domestic shipping within the USMCA region, today announced a significant collaboration with Envases Universales, one of the largest packaging companies worldwide. According to the announcement, Fr8App was awarded key routes through Envases’ annual 2024 RFQ, underscoring its commitment to delivering exceptional transportation services and its capability to meet the evolving needs of its clients. “We are thrilled to have been chosen by Envases Universales to help manage their transportation needs over the coming year,” said Fr8App’s CEO Javier Selgas. “This collaboration not only speaks to our capabilities but also to the trust Envases Universales has in our ability to deliver exceptional service. It also highlights the importance of tactical collaboration between the companies in driving profitable growth and achieving excellence in dependable and efficient logistics execution.”
Freight Technologies (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process. Its wholly owned subsidiary, Freight App Inc. (“Fr8App”), is a B2B cross-border shipping marketplace in the USMCA region powered by AI and machine learning. Focused on making shipping transparent and efficient, Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road (“OTR”) shipping. Fr8App uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via innovative technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions. The company is headquartered in Houston, Texas. For more information, please visit Fr8Technologies.com.
NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
SOBRsafe (NASDAQ: SOBR), providers of next-generation transdermal alcohol detection solutions, is partnering with TráTek Monitoring Services to expand its footprint in Canada. The company announced that TráTek, which is based in British Columbia, has signed an agreement to adopt its SOBRsafe technology for use in its family law practice with voluntary pretrial clients. In conjunction with the agreement, TráTek has purchased multiple SOBRcheck(TM) and SOBRsure(TM) devices. TráTek has become a licensed channel partner of alcohol monitoring technologies and works to support the legal system across Canada. According to the announcement, the company plans to deploy SOBRsafe solutions nationwide through its regional sales manager model; TráTek is also evaluating SOBRsafe technology for potential use the Canadian over-the-road trucking market.
According to a TráTek official, SOBRsafe technology is much easier to use, delivers faster results and is less expensive for the user than current options. “This relationship with TráTek accomplishes two key goals for SOBRsafe: 1) it gets our technology in immediate live use in Canada, and 2) it places motivated ‘boots on the ground’ for us across all provinces at no upfront or fixed costs to SOBRSafe,” said SOBRsafe chair and CEO Dave Gandini in the press release. “We feel that TráTek is an ideal organization for growing our brand and business interests in Canada.”
SOBRsafe offers an advanced transdermal (touch-based) technology that detects and reports in real time the presence of alcohol as emitted through a user’s skin — no breath, blood or urine sample is required. Alcohol misuse is the fourth leading cause of preventable death in America and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive, inefficient, unhygienic and unconnected. There has to be a better way. Enter SOBRsafe. With a powerful backend data platform, SOBRsafe provides next-generation, passive-detection technology for the behavioral health, judicial and consumer markets, as well as for licensing and integration. The SOBRsafe technology is commercially available for access control (SOBRcheck), wearable use (SOBRsure) and licensing/white labeling. SOBRsafe is creating a culture of prevention and support. For more information about SOBRsafe, visit www.SOBRsafe.com.
NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at http://ibn.fm/SOBR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Astrotech reported financial results for the quarter ended December 31, 2023, recording year-to-date revenue of $1,540,000
The company attributed the growth to the successful fulfillment of two significant purchase orders for the TRACER 1000(TM), the world’s first mass spectrometer-based explosive trace detectors (“ETD”), to customers in Romania
Astrotech is focused on commercializing its innovative platform mass spectrometry technology through its wholly owned subsidiaries 1st Detect Corp., AgLAB Inc., Pro-Control Inc., and BreathTech Corp.
The company and its subsidiaries are positioned to capitalize on burgeoning markets, including the global mass spectrometry market, expected to grow from an estimated $6.77 billion in 2024 to $9.17 billion by 2029
Astrotech (NASDAQ: ASTC), a science and technology development and commercialization company, focused on commercializing its innovative platform mass spectrometry technology through its wholly owned subsidiaries, recently released financial results for the three months ended December 31, 2023 (“Q2 2024”).
The company recorded a 512% jump in its year-to-date (“YTD”) revenue to $1,540,000 from $301,000 in the comparative period a year before. Astrotech attributed this growth primarily to two significant purchase orders for the TRACER 1000(TM) explosive trace detectors (“ETDs”) to customers in…
NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://cnw.fm/ASTC
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
Lexaria, a global innovator in drug delivery platforms, just announced $3.6 million in gross proceeds from its registered direct offering priced at the market
The proceeds will go to critical R&D studies, patent, and legal costs, as well as general working capital purposes
This is timely, given Lexaria’s resolve to double down on GLP-1 investigations for the 2024 calendar year
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that the registered direct offering for the purchase and sale of 1,558,443 shares of common stock at a purchase price of $2.31 – at the market under Nasdaq rules – per share yielded approximately $3.6 million in gross proceeds. This was offered by the company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-262402), and it opens Lexaria to important new opportunities for the 2024 calendar year (https://cnw.fm/9CHup).
Most notably, Lexaria intends to use the net proceeds from this offering for research and development (“R&D”) studies, and the associated patent and legal costs. It also intends to use the funds for general working capital purposes, important for its current focus on GLP-1 clinical studies for the…
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s and multiple sclerosis (“MS”). “The company’s lead drug candidate is CNM-Au8, an innovative nanomedicine uniting the principles of physics, chemistry, materials science, and biology to address neurodegenerative diseases from a new angle. Clene uses catalytic boosting of energy metabolism to enable dying neurons to resist the multiple stressors associated with disease, allowing them not only to survive but also to function,” a recent article reads. The article discusses CNM-Au8 development pathways, which have included: a Phase 2 VISIONARY trial in MS; two Phase 2 brain imaging studies, REPAIR-MS and REPAIR-PD, in participants with MS and PD; RESCUE-ALS, a nine-month, Phase 2 study that investigated CNM-Au8 for efficacy and safety in early-stage ALS participants; and a HEALEY-ALS Platform trial, a six-month, Phase 2 study that investigated CNM-Au8 for efficacy and safety in participants with ALS. “During 2024, Clene will work with the U.S. FDA to consider the strength of Clene’s data while exploring all potential pathways to commercialization, including the possibility of accelerated approval based upon a biomarker and/or survival signal. With the supportive efficacy data and additional biomarker data in the pipeline, the company believes that the development path for CNM-Au8 looks bright in 2024.”
Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is reporting on its continued focus on the commercial vehicle segment with production and deliveries of its Class 1 and Class 3 commercial EVs. According to the announcement, the company is in full commercial production of the Class 1 and Class 3 EV vehicles while subsidiary Bollinger Motors is focused on Class 4–6 vehicles; production of the Class 4 EV is set to begin in the second half of 2024. In addition, Mullen saw positive gross margin per Class 1 and Class 3 vehicles invoiced. The company also noted that it is integrating advance battery solutions and artificial intelligence (“AI”)-driven battery management systems.
“Strategically, in 2022 we understood EV adoption in the commercial sector would occur faster and doubled down on our acquisition efforts with both the majority acquisition of Bollinger Motors and the purchase of Electric Last Mile Solutions assets, which included full ownership of a large automotive manufacturing facility in Mishawaka, Indiana,” said Mullen Automotive CEO and chair David Michery in the press release. “These acquisitions allowed us to scale faster, which is best demonstrated by the launch of commercial vehicle production and customer deliveries in 2023. Mullen’s effort will be matched when Bollinger begins Class 4 production launch, which is planned later in 2024. Our effort on the commercial segment is laser focused, and the opportunity has never been better with increased demand seen across all our commercial vehicle offerings.”
Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. In 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive and Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP as well as a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
Vision Marine Technologies (NASDAQ: VMAR), an innovator in the performance electric recreational boating industry, has entered into a “groundbreaking” partnership with Nautical Ventures Marine Group. According to the announcement, partnership includes an initial purchase order (“PO”) for 50 of VMAR’s innovative rotomolded, recyclable boat, known as the Phantom. In addition, the agreement establishes an exclusive distributorship arrangement between the two companies, identifying Nautical Ventures Marine Group, a premier provider of maritime products and services, as the sole distributor of the Phantom in the growing South Florida market. The company observed that the Phantom has already established a reputation for its sustainable design and ecofriendly footprint, being constructed from fully recyclable materials; delivery of the 50 units of the Phantom will made over the next four months. “Vision Marine Technologies is excited to partner with Nautical Ventures Marine Group, a company that shares our commitment to innovation, quality, and environmental stewardship,” said Vision Marine Technologies CEO Alex Mongeon in the press release. “This partnership and the initial order of 50 units are a testament to the Phantom’s unique value proposition and our shared vision for a greener future in maritime recreation.”
Vision Marine also noted that it has received notification that the company is not in compliance with NASDAQ’s minimum bid price requirement. The company has been granted a compliance period of 180 calendar days to regain compliance with the requirement.
Vision Marine Technologies epitomizes the marine industry’s shift toward electric propulsion, offering the pioneering E-Motion(TM) outboard powertrain system. This innovative technology represents a significant leap forward in marine propulsion, combining advanced battery packs, inverters and high-efficiency motors with proprietary software and assembly techniques. Vision Marine’s commitment to ecofriendly electric powerboats is reshaping the recreational boating experience, offering higher speeds, longer ranges and smoother rides than traditional internal combustion engine boats. With a focus on design, innovation and craftsmanship, Vision Marine continues to redefine recreational boating for a more sustainable future. For more information about the company, please visit www.VisionMarineTechnologies.com.
NOTE TO INVESTORS: The latest news and updates relating to VMAR are available in the company’s newsroom at http://ibn.fm/VMAR
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
Arizona-based SenesTech has developed a portfolio of rodent birth control products as a very effective alternative to deadly poisons often used to control rat populations
SenesTech’s most recent product rollout is a soft bait formulation of its Birth Control for Rats(TM) branded Evolve(TM), in response to pest management businesses that prefer solid baits to SenesTech’s initial liquid products
The company recently announced a partner agreement with grain management market distributor Poppe Enterprises to stock Evolve(TM) at outlets in states from North Dakota to Kansas and Colorado, following on the heels of a similar agricultural distribution agreement with a global irrigation solutions company
Rodent pest control enterprise SenesTech (NASDAQ: SNES) is based in Arizona has begun to establish a global reach for its innovative Birth Control for Rats(TM) products, and the company is expanding its operations within agricultural sectors where rodent predation may otherwise have costly effects on…
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
SuperCom, a global leading provider of digital identity and electronic monitoring (“EM”) solutions, has announced a new contract with an established California services provider in the judicial sector
This marks the second closed contract in 2024, a milestone that Ordan Trabelsi, President and CEO of SuperCom, has attributed mainly to the company’s introduction of its PureOne technology
According to Mr. Trabelsi, this milestone showcases SuperCom’s ability to compete in the market successfully and its commitment to innovation and customer satisfaction
SuperCom (NASDAQ: SPCB), a leading global provider of digital identity and EM solutions, offering advanced identification and security products to governments, has announced a new contract with an established California services provider in the judicial sector. This marks the second closed contract for the 2024 calendar year. “We are pleased to announce a second new contract in North America since the start of 2024, reflecting momentum and reputation in the industry,” noted Ordan Trabelsi, SuperCom’s President and CEO. “This collaboration showcases not only our ability to compete in the market successfully but also our commitment to innovation and customer satisfaction,” he added (https://ibn.fm/C3B44).
The partnership with a new client showcases SuperCom’s capability to establish important new connections in the US. The flexible contract structure opens significant scaling and long-term…
NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Turbo Energy (NASDAQ: TURB) is a European innovator designing, developing and manufacturing photovoltaic energy generation, management and storage equipment. “Boasting cutting-edge products labeled as ‘the market’s most advanced AI-driven energy management system,’ Turbo Energy makes no secret of its ambitious goals. In this dynamic landscape of AI-driven green energy, the company aims to position itself as a key player with a bold mission ‘to protect the world from energy and economic crisis,’” a recent article reads. “Turbo Energy recently released its flagship product, Sunbox, an all-in-one device for residential solar installations powered by AI capable of connecting to everything. Sunbox’s software analyzes energy data, optimizes battery usage, reduces bills, and provides peak-use reduction and uninterruptible power supply functions. With the 2023 launch of higher-power models, Turbo Energy plans to expand Sunbox internationally into industrial and commercial markets.”
Turbo Energy is a leading photovoltaic energy storage technology company based in Valencia, Spain. The company develops innovative solutions that allow end users to harness the full potential of solar energy and reduce their electricity costs. With a combination of artificial intelligence and advanced technology, Turbo Energy is paving the way toward a more sustainable and energy-efficient future. For more information, visit the company’s website at www.Turbo-E.com.
NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB
About GreenEnergyStocks
GreenEnergyStocks (“GES”) is a specialized communications platform with a focus on companies working to shape the future of the green economy. GreenEnergyStocks is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GES is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, GES brings its clients unparalleled recognition and brand awareness. GES is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from GreenEnergyStocks, text “Green” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the GreenEnergyStocks website applicable to all content provided by GES, wherever published or re-published: https://www.greennrgstocks.com/Disclaimer
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has scheduled a conference call to discuss its financial results for 2023. The company announced that it will release its 2023 financial results after market close on Feb. 27, 2024, and will host a conference call at 5 p.m. ET that same day. During the call, company officials will provide an overview of the financial report as well as a corporate update. Those interested in participating on the call can dial 1-877-407-0789, then use conference ID 13744350.
Longeveron is a clinical-stage, biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action encompassing provascular, proregenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently advancing Lomecel-B through clinical trials in three indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty. To learn more about the company, visit www.Longeveron.com.
NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://ibn.fm/LGVN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today reported new, significant survival results in amyotrophic lateral sclerosis (“ALS”) patients. According to the announcement, the results are from two independent analyses of pooled data from two intermediate-size “Companionate Use” Expanded Access Programs (“EAPs”) supported by the company. The EAPs provided access to treatment with CNM-Au8(R) to 256 participants, all people living with ALS who were generally too advanced in their disease to qualify for clinical trials. According to the announcement, a pooled survival analysis of EAP participants treated with CNM-Au8 30 mg was compared to two independent datasets derived from PRO-Act and the ALS/MND Natural History Consortium. “The results in the EAP participants versus the matched controls demonstrated a significant benefit for each comparison,” the announcement stated. “Analysis including all 256 EAP participants compared to the 220 matched controls also showed statistically significant survival benefits with long-rank p-values of p < 0.0001 and p=0.006 for the PRO-ACT and ALS/MND Natural History Consortium matched controls, respectively.”
Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) is a technology company with a custom-developed, industry-leading Fr8App freight-matching platform offering a real-time portal for B2B cross-border and domestic shipping within the USMCA region. The company previously announced its receipt, in August 2023, of written notification from the Nasdaq Stock Market LLC that it did not comply with the minimum bid price requirement for continued listing on the Nasdaq Capital Market per Listing Rule 5550(a)(2) because the closing bid price for the company’s ordinary shares had fallen below $1.00 per share for 30 consecutive business days. On Feb. 20, 2024, Fr8Tech received notification that Nasdaq staff had determined that for the last 10 consecutive business days, from Feb. 5 through Feb. 16, 2024, the closing bid price of the company’s ordinary shares had been at $1.00 per share or greater. Accordingly, the company has regained compliance with Nasdaq’s minimum bid price listing rule, and the matter is now closed.
Freight Technologies (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process. Its wholly owned subsidiary, Freight App Inc. (“Fr8App”), is a B2B cross-border shipping marketplace in the USMCA region powered by AI and machine learning. Focused on making shipping transparent and efficient, Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road (“OTR”) shipping. Fr8App uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via innovative technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions. The company is headquartered in Houston, Texas. For more information, please visit Fr8Technologies.com.
NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
Astrotech’s (NASDAQ: ASTC) subsidiary AgLAB, Inc. has breakthrough mass spectrometry technology in its AgLAB 1000-D2 mass spectrometer and the Maximum Value Process(TM) testing method (“AgLAB MVP”). “AgLAB MVP is designed to improve yields and bottom-line profits for hemp (‘CBD’) and cannabis (‘THC’) producers of CBD-THC oils by up to 30%. Large-scale CBD and THC oil processors use molecular distillation systems (‘MDS’) to produce the valuable oils that are used in lotions, pills, tinctures, and cartridges. Using the AgLAB MVP solution, customers are now able to analyze the oils during processing and make near real-time adjustments that can boost the ending-weight yields and potencies,” a recent article reads. “We are proud to introduce the AgLAB MVP, a breakthrough technology that is more accurate and faster than any other testing method. The AgLAB MVP is very fast and is easy to learn with results that more than pay for itself starting on the first day of use. We believe this is a game changer for the cannabinoid industry and processors must use the AgLAB MVP to stay competitive,” Tom Pickens, CEO and CTO of Astrotech, was quoted as saying.
Astrotech is an innovative science and technology company that invents, acquires and commercializes technological innovations while building scalable companies to maximize shareholder value. For more information, please visit www.AstrotechCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Longeveron’s (NASDAQ: LGVN) extended long-term follow-up data from the ELPIS I study was presented as a poster at the annual Scientific Sessions of the American Heart Association (“AHA”). “ELPIS I was designed to assess the safety and potential efficacy of intramyocardial injection of Lomecel-B(TM) administered to 10 infants with hypoplastic left heart syndrome (‘HLHS’) during Stage II surgeries at approximately 4 months of age. The study met the primary safety endpoint: no major adverse cardiac events or any treatment-related infections during the first month post-treatment were reported. Moreover, secondary endpoints measured per protocol suggested Lomecel-B injection may improve patient long-term clinical outcome post-surgery. While the positive results permitted the transition to a Phase II randomized, double-blind, controlled trial, ELPIS II, with enrollment commencing in July 2021, investigators elected to extend follow-up of the 10 infants after ELPIS I came to its planned end for a total period of five years,” a recent article reads. “Long-term follow-up data from our ELPIS I trial demonstrate the continued survival of the participants and reinforce potential survival benefit of Lomecel-B for patients with HLHS,” Joshua M. Hare, Longeveron’s co-founder, chief science officer, and chair of the board of directors, is quoted as saying.
Longeveron is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM) an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently advancing Lomecel-B through clinical trials in three indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty. Additional information about the company is available at www.Longeveron.com.
NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at http://ibn.fm/LGVN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Arizona-based SenesTech Inc., is dramatically improving pest management technicians’ toolbox with its patent-pending Evolve(R) soft bait birth control product for rodents
SenesTech’s Evolve(R) product joins the liquid ContraPest(TM) product in providing a non-lethal solutions to reducing rodent populations
The company’s CEO and CFO recently appeared virtually at the Lytham Partners 2024 Investor Select Conference, participating in a fireside chat interview and meeting one-on-one with potential investors
SenesTech also recently announced increased distribution of its product in partnership with Poppe Enterprises LLC, — a company that serves the grain management market in Nebraska, South Dakota, North Dakota, Kansas, Wyoming, Iowa, and Colorado
The chief officers of enterprising rodent control company SenesTech (NASDAQ: SNES) participated in a fireside chat interview detailing the company’s operations and also met with potential investors one-on-one at this month’s virtual Lytham Partners 2024 Investor Select Conference.
CEO Joel Fruendt and CFO Tom Chesterman enjoyed the opportunity to discuss the breakout success of its non-lethal Evolve(TM) Soft Bait product following on the heels of successful implementation of its original liquid bait formulation ContraPest(R), which, like Evolve(TM), is designed to reduce…
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
SuperCom, a global provider of digital identity and electronic monitoring (“EM”) solutions, just announced a new project in the tracking sector with a renowned Canadian industry partner
The initial phase of the project is set to launch in the first quarter of the 2024 calendar year, with significant potential for expansion in both scale and scope
The project will include the transition from RF-based tracking technology to new GPS tech using SuperCom’s PureOne devices
SuperCom (NASDAQ: SPCB), a global leading provider of digital identity and electronic monitoring solutions and services to governments and institutions, just announced a new project with a renowned Canadian industry partner in the tracking solutions sector. This marks an impressive start to the new year and a healthy addition to SuperCom’s current client and project portfolio, comprising governments and notable institutions in over 10 countries (https://ibn.fm/pmZRq).
The new project comes in the wake of the growing realization that offender monitoring solutions reduce recidivism among offenders. In a study conducted by Jenny Williams and Don Weatherburn, it was established that electronic monitoring for offenders was associated with a 25% reduction in the…
NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
SOBRsafe (NASDAQ: SOBR), providers of next-generation transdermal alcohol detection solutions, announced that ALYST Health has selected the SOBRsafe(TM) technology to use in its concierge addiction treatment services. ALYST offers the first and only at-home addiction-treatment program accredited by the Joint Commission, which is the oldest and largest health care standards-setting body in the country. According to the announcement, ALYST has purchased a supply of SOBRsure(TM) alcohol-detection wristbands with plans to use them as a more flexible, humane fully at-home alcohol treatment program. ALYST company officials noted that conventional treatment centers and conventional monitoring methods don’t always provide privacy or personalized treatment. With the addition of SOBRsure to its program, ALYST can move the point of care from the treatment center to the comfort and privacy of a client’s home without sacrificing quality and while offering dignity and remote monitoring, which the company believes will empower recovery success. “We are honored to work with ALYST, a standard-bearer for behavioral health innovation,” said SOBRsafe chair and CEO Dave Gandini in the press release. “We both seek to optimize recovery outcomes by looking beyond the walls of traditional treatment.”
SOBRsafe offers an advanced transdermal (touch-based) technology that detects and instantaneously reports the presence of alcohol as emitted through a user’s skin — no breath, blood or urine sample is required. Alcohol misuse is the fourth leading cause of preventable death in America and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive, inefficient, unhygienic and unconnected. There has to be a better way. Enter SOBRsafe. With a powerful backend data platform, SOBRsafe provides next-generation, passive-detection technology for the behavioral health, judicial and consumer markets, as well as for licensing and integration. The SOBRsafe technology is commercially available for access control (SOBRcheck), wearable use (SOBRsure) and licensing/white labeling. SOBRsafe is creating a culture of prevention and support. For more information about SOBRsafe, visit www.SOBRsafe.com.
NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at http://ibn.fm/SOBR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is reporting an update on its U.S. Customs and Border Protection (“CBP”) application for Class 1 EV cargo vans. According to the update, CBP notified counsel on Feb. 20, 2024, that a determination on the ruling request should be made in the next one to two months. The company noted that CBP ruling requests are typically processed on a first-in, first-out basis and that decisions are usually made between 45 to 90 days, although some decisions may take longer, depending on the agency’s caseload. “On Nov. 24, 2023, Mullen and Rapid Response Defense Systems filed responses for final ruling and compliance by the U.S. Customs and Border Protection application for Mullen’s Class 1 EV cargo van,” stated the company in the press release. “If Mullen receives a favorable final ruling, the company will be immediately eligible to sell Class 1 EV cargo vans to all branches of U.S. government.”
Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. In 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive and Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP as well as a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has closed on a registered direct offering. The offering included the purchase and sale of 1,558,443 shares of common stock (or common stock equivalents in lieu thereof) offered at $2.31 per share. The company also noted that, in a concurrent private placement, it issued unregistered warrants to purchase up to 1,558,443 shares of common stock. The shares were offered at an exercise price of $2.185 per share and were immediately exercisable upon issuance with an expiration date five years following the date of issuance. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. “The gross proceeds to the company from the offering were approximately $3.6 million before deducting placement agent fees and other offering expenses payable by the company,” the announcement stated. “The company intends to use the net proceeds from the offering for research and development studies and the patent and legal costs associated thereto, and for general working capital purposes.”
Lexaria Bioscience’s patented drug-delivery formulation and processing platform technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
Turbo Energy (NASDAQ: TURB) is a designer, developer and manufacturer of photovoltaic energy generation, management and storage equipment. The company has sought to address solutions in the rapidly growing residential solar market in Europe. “The company’s ‘SunBox Home’ system encompasses an all-in-one AI-powered energy storage solution, designed to assist households in managing their power consumption. Directly linked to a household’s solar panel generation unit, the SunBox system allows users to choose between settings including ‘maximum consumption’ or ‘maximum savings,’ conserve a portion of its energy reserves in the event of unexpected electricity blackouts or, rather, sell excess power back onto the grid. The groundbreaking energy storage system additionally boasts the capacity to track weather forecasts, thus ensuring its batteries are fully charged in the event of a storm,” a recent article reads. “Artificial intelligence, as harnessed by Turbo Energy’s innovative energy storage systems, is playing an increasingly transformative role in advancing energy storage technologies, optimizing battery performance, and improving the overall effectiveness of these technologies… As both a leading European purveyor of household solar energy systems as well as an early mover in the inclusion of generative AI technologies within its revolutionary renewable energy storage solutions, Turbo Energy is well placed to play an increasingly prominent role in fueling Europe’s renewable energy evolution going forward.”
Turbo Energy is a leading photovoltaic energy storage technology company based in Valencia, Spain. The company develops innovative solutions that allow end users to harness the full potential of solar energy and reduce their electricity costs. With a combination of artificial intelligence and advanced technology, Turbo Energy is paving the way toward a more sustainable and energy-efficient future. For more information, visit the company’s website at www.Turbo-E.com.
NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB
About GreenEnergyStocks
GreenEnergyStocks (“GES”) is a specialized communications platform with a focus on companies working to shape the future of the green economy. GreenEnergyStocks is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GES is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, GES brings its clients unparalleled recognition and brand awareness. GES is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from GreenEnergyStocks, text “Green” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the GreenEnergyStocks website applicable to all content provided by GES, wherever published or re-published: https://www.greennrgstocks.com/Disclaimer
SOBRsafe recently published three case studies that empirically demonstrate the performance of its alcohol screening technology, SOBRcheck(TM), based on customer data, experiences, and results
SOBRcheck can be used as a safe, convenient, and fast replacement for cumbersome and unhygienic breathalyzers
One case study shows that SOBRcheck enabled TerraTech to achieve a 100% pass rate per week against an estimated industry average weekly violator rate of between 60% and 70%
By deploying SOBRcheck, Big Horn County has been able to provide cost-effective alcohol monitoring services for more than 100 community members, while Alternatives Inc. has achieved 4x faster throughput at check-in/check-out
SOBRsafe CEO recently provided a comprehensive update on the company in a fireside chat video
A disruptive company leveraging advanced alcohol detection approaches and technologies, SOBRsafe (NASDAQ: SOBR) is a provider of next-generation touch-based alcohol screening, detection, and monitoring solutions, as well as real-time reporting software. Among these revolutionary solutions is SOBRcheck(TM).
A stationary identification and alcohol screening/monitoring technology launched in 2021, SOBRcheck detects and instantaneously reports the presence of alcohol emitted through the pores of a fingertip. It is equipped with a biometric identifier that automatically confirms the user’s identity and hardcodes this…
NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, recently reported new results from a long-term open-label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis (“RMS”) totaling nearly three years of follow up. Data from the study show clear overall improvements in vision and cognition for participants treated for nearly three years from randomization, with these results robust and consistent, according to Professor Michael Barnett, Professor of Neurology, Brain and Mind Centre, University of Sydney, and one of the trial’s key clinical advisors. “Clene is closely studying CNM-Au8(R) because a drug that may halt MS disease progression and may even improve function on top of standard-of-care MS therapies would represent a milestone achievement in drug development for this disease,” a recent article reads. “These data continue to build a strong case in favor of pursuing CNM-Au8 in upcoming Phase 3 studies. Clinically significant improvement is rarely seen in MS patients, and this trial provides evidence of CNM-Au8’s potential to improve function in this population,” Dr. Benjamin Greenberg, M.D., Head of Medicine at Clene, is quoted as saying.
Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
Freight Technologies (NASDAQ: FRGT), a technology company whose custom-developed Fr8App, an industry-leading freight-matching platform powered by artificial intelligence (“AI”) and machine-learning and offering a real-time portal for B2B cross-border shipping and domestic shipping within the USMCA region, is participating in this month’s Geotab Connect 2024 event. The company received a special invitation to participate in the prestigious event, which is hosted by Geotab, a global leader in connected transportation solutions. The event was held from Feb. 14–16 in Las Vegas. According to the announcement, the three-day Geotab Connect 2024 event is designed to offer unparalleled insights into the ever-evolving landscape of connected vehicles, data intelligence, artificial intelligence and sustainability. Fr8App was a distinguished marketplace partner for the event.
“We are thrilled to continue being marketplace partners with such a prominent company in the technology and logistics industry like Geotab,” said Fr8App CEO Javier Selgas in the press release. “Fr8App has been able to significantly enhance the user experience for shippers and carriers on its platform with Geotab’s telematics, and we look forward to bringing further innovations to our customers and partners through collaboration and contribution to Geotab’s ecosystem.”
Freight Technologies is a technology company developing solutions to optimize and automate the supply chain process. Its wholly owned subsidiary, Freight App Inc. (“Fr8App”), is a business-to-business, cross-border shipping marketplace in the United States-Mexico-Canada Agreement (“USMCA”) region powered by artificial intelligence (“AI”) and machine learning. Focused on making shipping transparent and efficient, Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road (“OTR”) shipping. Fr8App uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via innovative technologies such as live pricing and real-time tracking, digital freight marketplace, transportation management, fleet management and committed capacity solutions. The company is headquartered in Houston, Texas. For more information about the company, please visit www.FR8Technologies.com.
NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal-pest populations, will be reporting its financial results for its fourth quarter and fiscal year 2023, or the period ended Dec. 31, 2023. The company has scheduled the release of the report for after market close on Feb. 21, 2024. In addition to releasing the report, the company has scheduled a teleconference for that same date to review the report; the call will begin at 5 p.m. ET. Those interested in participating in the call can dial (844) 308-3351 or (412) 317-5407. A replay of the teleconference will be available for seven days following the event; those interested in viewing the replay can dial (877) 344-7529 or (412) 317-0088, using replay access code 3232725.
SenesTech is committed to improving the health of the world by humanely managing animal-pest populations through fertility control. SenesTech is an expert in fertility control to manage animal pest populations. The company invented ContraPest, the only U.S. EPA-registered contraceptive for male and female rats, and Evolve, an EPA-designated minimum-risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest-management programs, significantly improving the overall goal of effective pest management. The company strives for clean cities, efficient businesses and happy households by providing a product designed to be humane, effective and sustainable. For more information about the company, please visit www.SenesTech.com.
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
“In the dynamic world of investments, electric boat stocks are gaining momentum,” reports InvestorPlace
The article calls Vision Marine a key player in the electric boat stocks market
VMAR’s recent partnerships, market expansion and production enhancements point to potential growth and innovation
As investors pay increasing attention to potential involvement in clean, green-energy companies, the idea of sustainability is becoming more of a priority in sectors across the board. Vision Marine Technologies (NASDAQ: VMAR), a global leader and innovator in the performance electric recreational boating industry, is capturing attention and was recently spotlighted in an InvestorPlace article titled “Three Electric Boat Stocks That Will Sail Higher by 2024” (https://ibn.fm/ZFu5W).
“In the dynamic world of investments, electric boat stocks are gaining momentum,” the article stated. “These ‘e-boat stocks’ blend innovation with eco-sustainability. They mark a significant shift in the…
NOTE TO INVESTORS: The latest news and updates relating to VMAR are available in the company’s newsroom at https://ibn.fm/VMAR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in the development and delivery of quantum computing systems, and Momentum Worldwide, a global experiential agency within Interpublic Group of Companies (NYSE:IPG), have been working together on a pilot project to optimize experiential marketing tours and events. Momentum Worldwide provides large-scale experiential marketing and promotional tours for an array of well-known clients.
The pilot project was featured in a recent “Fast Company” column from Momentum Worldwide global chief technology officer Jason Snyder, highlighting how quantum computing can be a practical solution for business problems. Titled “How Quantum Computing Technology Solves Real-World Business Challenges,” the column noted that quantum computing is a multidisciplinary field that incorporates aspects of physics, mathematics and computer science, using principles of quantum mechanics to tackle complex problems that classical computing can’t efficiently solve.
“Quantum computing represents a transformative leap in technology,” said Snyder in the column. “This advancement is not just theoretical; it’s applicable and valuable in real-world business scenarios in various sectors. For the marketing industry, it marks significant progress toward more sophisticated, efficient, and eco-friendly operational models.”
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations, including Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California and Los Alamos National Laboratory. For more information about the company, please visit www.dwavequantum.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the implementation of the initiatives established by the NDAA and the development and implementation of other Congressional initiatives related to quantum technology. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the successful implementation of the initiatives and programs established by the NDAA; whether the other pieces of legislation related to Congressional initiatives regarding quantum technology continue to proceed through the legislative process; general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on the company’s business; the risk that D-Wave will need to raise additional capital to execute the company’s business plan, which may not be available on acceptable terms or at all; the risk that D-Wave may never achieve or sustain profitability; the risk that D-Wave is unable to secure or protect the company’s intellectual property; volatility in the price of the company’s securities; the risk that the company’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, today announced its entry into a distribution agreement with Q-chem, a pest control product supplier in the Netherlands. SenesTech has developed and is commercializing a proprietary technology for managing animal pest populations, primarily rat populations, through fertility control. “Q-chem is a perfect partner for SenesTech as we begin our expansion into Europe, and Evolve(TM) fits into their portfolio perfectly,” said Joel Fruendt, SenesTech’s president and CEO. “They have a stated focus on new, environmentally friendly and sustainable products for pest control, and they distribute pest control products in the Netherlands and specifically non-biocidal products throughout Europe.”
SenesTech is committed to improving the health of the world by humanely managing animal pest populations through fertility control. The company is an expert in fertility control to manage animal pest populations. It invented ContraPest(R), the only U.S. EPA-registered contraceptive for male and female rats, and Evolve(TM), an EPA-designated minimum risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. SenesTech strives for clean cities, efficient businesses and happy households – with a product designed to be humane, effective and sustainable. For more information about the company, visit www.SenesTech.com.
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
Vision Marine Technologies (NASDAQ: VMAR), an innovator in the performance electric recreational boating industry, has unveiled its newest offering: the Phantom. The company announced the new rotomolded, recyclable and hard-to-damage boat at the Miami International Boat Show 2024. According to the announcement, the Phantom is a breakthrough in rotomolded boat design that offers significant market advantages through its economic and environmental benefits. The company anticipates producing an estimated 300 units annually at 70% less than the production costs of fiberglass alternatives, with potential scalability to 1,500 units per year. In addition, Vision Marine announced that it has entered an exclusive distribution agreement with Nautical Ventures Marine Group for Florida, reflecting market confidence in the Phantom. The agreement calls for an initial order of 50 units. The Phantom’s launch represents VMAR’s commitment to innovation, durability and environmental stewardship. Nautical Ventures Group offers top-quality water sports products and support. “We recognize a growing demand for rotomolded boats among our Florida clientele for several reasons: their affordability enables entry-level ownership; they support both electric and gas motors, appealing to eco-conscious and traditional boaters alike; and their versatility makes the Phantom ideal for various activities, from fishing to leisure,” said Nautical Ventures CEO Roger Moore in the press release. “With its 10-person capacity and maintenance-free design, the Phantom meets a wide range of needs.”
Vision Marine Technologies epitomizes the marine industry’s shift toward electric propulsion, offering the pioneering E-Motion(TM) outboard powertrain system. This innovative technology represents a significant leap forward in marine propulsion, combining advanced battery packs, inverters and high-efficiency motors with proprietary software and assembly techniques. Vision Marine’s commitment to ecofriendly electric powerboats is reshaping the recreational boating experience, offering higher speeds, longer ranges and smoother rides than traditional internal combustion engine boats. With a focus on design, innovation and craftsmanship, Vision Marine continues to redefine recreational boating for a more sustainable future. For more information about the company, please visit www.VisionMarineTechnologies.com.
NOTE TO INVESTORS: The latest news and updates relating to VMAR are available in the company’s newsroom at http://ibn.fm/VMAR
About GreenEnergyStocks
GreenEnergyStocks (“GES”) is a specialized communications platform with a focus on companies working to shape the future of the green economy. GreenEnergyStocks is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GES is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, GES brings its clients unparalleled recognition and brand awareness. GES is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from GreenEnergyStocks, text “Green” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the GreenEnergyStocks website applicable to all content provided by GES, wherever published or re-published: https://www.greennrgstocks.com/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has entered into definitive agreements. The agreements are for the purchase and sale of 1,558,443 shares of common stock (or common stock equivalents in lieu thereof) offered at $2.31 per share (or per common stock equivalent in lieu thereof). The agreements are part of a registered direct offering priced in adherence with NASDAQ rules. In addition, the company noted that in a concurrent private placement, it will issue unregistered warrants to purchase up to 1,558,443 shares of common stock. Those shares will be offered at an exercise price of $2.185 per share, exercisable upon issuance and with an expiration date of five years following the date of issuance. The company anticipates closing on the offering on or about Feb. 16, 2024. Lexaria projects funds from the offering to total an estimated $3.6 million before deductions and fees; the company plans to use the funds for research and development studies and the patent and legal costs, as well as for general working capital purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Lexaria Bioscience’s patented drug-delivery formulation and processing platform technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, and its subsidiary Bollinger Motors have announced that Bollinger has contracted with its first authorized dealership. Bollinger is partnering with LaFontaine Automotive Group, which has two locations in Michigan: Lansing and Farmington Hills. LaFontaine will offer the Bollinger B4 Chassis Cab, which is an all-new, all-electric class 4 commercial truck designed from the ground up with extensive fleet and upfitter input; the announcement noted that deliveries of the B4 chassis cab are expected to begin in the second half of 2024. LaFontaine observed that the new collaboration increases the company’s portfolio to 54 retail franchises and 39 retail locations, with more planned later this year. LaFontaine officials stated that the Bollinger partnership reflects the company’s commitment to providing its commercial customers with a personalized experience that extends far past the sale of the vehicle and aligns with its long-term vision of growth and expansion. “Our strategically developed plan to offer sales and service nationwide is being kicked off with LaFontaine,” said Bollinger Motors chief revenue officer Jim Connelly in the press release. “Additional dealer partners will be announced soon, showing our commitment to fleets in all 50 states.”
Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. During 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive and Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP as well as a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in the development and delivery of quantum computing systems, software and services and the world’s first commercial supplier of quantum computers, has announced that the Advantage2 prototype, which features 1,200+ qubits and 10,000+ couplers, is now available via the company’s LeapTM real-time quantum cloud service. According to D-Wave, customers with Leap service subscriptions can access the new Advantage2 prototype today. Those new to the Leap service can sign up and get up to one minute of free use of the actual quantum processing units (“QPUs”) and quantum hybrid solvers, including the new Advantage2 prototype.
“Today marks an important milestone in our product delivery roadmap, as we open up access to the newest Advantage2 prototype for businesses, developers and researchers across the globe,” said Mark W. Johnson, senior vice president of quantum technologies and systems products at D-Wave. “What we’re seeing with the Advantage2 prototype in terms of performance gains is remarkable, and we’re thrilled to make it available today to help customers start applying it to their complex problems now.”
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations including Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory. For more information, visit the company’s website at www.dwavequantum.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the implementation of the initiatives established by the NDAA and the development and implementation of other Congressional initiatives related to quantum technology. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the successful implementation of the initiatives and programs established by the NDAA; whether the other pieces of legislation related to Congressional initiatives regarding quantum technology continue to proceed through the legislative process; general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on the company’s business; the risk that D-Wave will need to raise additional capital to execute the company’s business plan, which may not be available on acceptable terms or at all; the risk that D-Wave may never achieve or sustain profitability; the risk that D-Wave is unable to secure or protect the company’s intellectual property; volatility in the price of the company’s securities; the risk that the company’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on its financial results for Q2 2024, the period ended Dec. 31, 2023. The company also provided a corporate update, including plans to advance two preclinical programs in Alzheimer’s and age-related macular degeneration. Highlights of the report included that the company closed the 2023 calendar year in a cash position of $9.5 million and with 164% revenue growth in business subsidiary, BayMedica. “This period was another strong operational quarter for the company, as we expanded our pharmaceutical pipeline with the launch of two new programs with a particular focus on proprietary small molecule drug development candidates,” said InMed Pharmaceuticals CEO Eric A. Adams in the press release. “As outlined in our 2024 business update last month, we have further accelerated our development efforts in both INM-901 as a potential multimodal treatment option for Alzheimer’s disease and INM-089 in the treatment of age-related macular degeneration. Our commercial subsidiary, BayMedica LLC, continues to grow revenues, up 164% compared to the same three-month period last year. In addition, we ended calendar year 2023 with a cash position of over $9.5 million, allowing us to pursue several material milestones throughout calendar 2024.”
InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
NetworkNewsWire Editorial Coverage: The raucous rumble of combustion engines is fading, systematically replaced by the high-performance hum of electric propulsion that’s transforming every aspect of transport. Electric cars have moved mainstream with both automakers and upstarts offering multiple mobility options. Now another market is being disrupted, as sleek electric boats glide across the water leaving nothing but a whisper of ripples in their wake. This surge in electrification isn’t just about a clean and green conscience; it’s about performance, convenience and a technological transition in mobility that may be as profound as the shift from the horse to the horseless carriage. The producer of the world’s most powerful and most technically advanced electric outboard motor on the market today, Vision Marine Technologies Inc. (NASDAQ: VMAR) (Profile), is a recognized global leader, innovator and disruptive force in the electrification of recreational boating. The company is at the vanguard of transition, challenging the status quo of conformity alongside big players such as Brunswick (NYSE: BC) and yacht purveyor MarineMax (NYSE: HZO) by electrifying the waterways much like Winnebago (NYSE: WGO) intends to do and what Telsa (NASDAQ: TSLA) has already accomplished on land.
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
Artificial Intelligence is expected to both, drive global energy consumption whilst simultaneously, increasing the efficiency of global power usage
Turbo Energy is seeking to harness artificial intelligence in the manufacture and development of their residential energy solutions, which allow households to capture and store solar energy
The Company has recently entered into an agreement with Solar360, the energy-focused subsidiary of Repsol and Telefonica, in a move to dramatically increase their distribution footprint
The growing demands of artificial intelligence (“AI”) are set to drive a sharp increase in data center storage capacity, with the latter expected to grow from 10.1 zettabytes (“ZB”) in 2023 to 21.0 ZB in 2027, a five-year compound annual growth rate of 18.5%. Whilst this increased storage capacity is set to drive a huge proliferation in data centers, it will similarly drive a significant surge in energy usage, with data centers forecast to consume over 1% of global electricity in the coming years (https://ibn.fm/G8Vaz). Nonetheless, AI is simultaneously being harnessed to reduce energy expenditure – Google recently revealed that its AI-driven approach to data center cooling had led to a reduction of about 40 percent in energy use, the equivalent to taking 64,000 cars off the road annually.
The use of artificial intelligence is gaining increased relevance in terms of tackling carbon emissions, with recent analysis by global consultants McKinsey suggesting that AI-enhanced manufacturing could reduce global greenhouse gas emissions by 10-20 percent. Similarly, and within the energy sector, the adoption…
NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Lexaria, a global innovator in drug delivery platforms, just announced the submission of its IND application with the FDA for its HYPER-H23-1 phase 1b hypertension clinical trial
This study will seek to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM) technology, specifically DehydraTECH-CBD, in hypertensive patients
Lexaria expects to build on success of its previous studies, which showed positive results and DehydraTECH-CBD’s potential to have broad therapeutic utility
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the submission of its much-anticipated Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for its HYPER-H23-1 phase 1b hypertension clinical trial. The submission follows a successful pre-IND meeting with the FDA, an integral step in the IND’s development and filing (https://cnw.fm/exwpC).
Titled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” this study will seek to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM) and specifically…
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CBDWire
CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.
CBDW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CBDWire, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as head of business development and sales. Halpert brings extensive pharmaceutical sales and marketing experience and joins Scinai following 14 years at Novartis, most recently having served as marketing and commercial excellence lead for cell and gene therapies for Central, Southern and Eastern Europe. “I am pleased to welcome Liat to Scinai,” said Amir Reichman, Scinai’s CEO. “Her pharmaceutical sales, marketing and leadership experience, in particular in Israel and Europe, align with our strategic decision to grow Scinai Bioservices CDMO into a trusted provider of drug development services, including for preclinical and clinical trials and GMP manufacturing for clinical supplies.”
Scinai is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and pre-clinical and clinical trial design and execution services to early stage biotech companies. For more information, visit the company’s website at www.Scinai.com.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
